The	O
Epstein-Barr	B-protein
virus	I-protein
oncogene	I-protein
product	I-protein
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF-kappaB	O
.	O

The	O
Epstein-Barr	O
virus	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
into	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	B-protein
is	O
a	O
constitutively	B-protein
activated	I-protein
receptor	I-protein
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl-terminal	B-protein
cytoplasmic	I-protein
tail	I-protein
.	O

One	O
transformation	B-protein
effector	I-protein
site	I-protein
(	O
TES1	B-protein
)	O
,	O
located	O
within	O
the	O
membrane	B-protein
proximal	I-protein
45	I-protein
residues	I-protein
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
factors	I-protein
.	O

Signals	O
from	O
TES1	B-protein
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	B-cell_type
,	O
but	O
most	O
lymphoblastoid	B-cell_type
cells	I-cell_type
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	B-protein
residues	I-protein
beyond	O
TES1	B-protein
fail	O
to	O
grow	O
as	O
long-term	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	B-protein
end	I-protein
of	O
the	O
cytoplasmic	B-protein
tail	I-protein
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	B-protein
effector	I-protein
site	I-protein
,	O
TES2	B-protein
.	O

A	O
yeast	O
two-hybrid	O
screen	O
identified	O
TES2	B-protein
interacting	I-protein
proteins	I-protein
,	O
including	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-associated	I-protein
death	I-protein
domain	I-protein
protein	I-protein
(	O
TRADD	B-protein
)	O
.	O

TRADD	B-protein
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild-type	B-protein
TES2	I-protein
and	O
not	O
with	O
isoleucine-mutated	B-protein
TES2	I-protein
.	O

TRADD	B-protein
associated	O
with	O
wild-type	B-protein
LMP1	I-protein
but	O
not	O
with	O
isoleucine-mutated	O
LMP1	B-protein
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	B-protein
constitutively	O
associated	O
with	O
LMP1	B-protein
in	O
EBV-transformed	B-cell_line
cells	I-cell_line
.	O

In	O
transfection	O
assays	O
,	O
TRADD	B-protein
and	O
TES2	B-protein
synergistically	O
mediated	O
high-level	O
NF-kappaB	B-protein
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	B-protein
appropriates	O
TRADD	B-protein
to	O
enable	O
efficient	O
long-term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High-level	O
NF-kappaB	B-protein
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long-term	O
outgrowth	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

94	NULL
,	NULL
pp	NULL
.	NULL

12592-12597	NULL
,	NULL
November	NULL
1997	NULL
Medical	NULL
Sciences	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
oncogene	NULL
product	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
engages	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
death	NULL
domain	NULL
protein	NULL
to	NULL
mediate	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
and	NULL
activate	NULL
NF-B	NULL
KEnnEtH	NULL
M.	NULL
IzumM	NULL
AND	NULL
D.	NULL
KiEer*	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
and	NULL
Medicine	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Eighth	NULL
Floor	NULL
Channing	NULL
Laboratories	NULL
,	NULL
181	NULL
Longwood	NULL
Avenue	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
Contributed	NULL
by	NULL
Elliott	NULL
D.	NULL
Kieff	NULL
,	NULL
September	NULL
22	NULL
,	NULL
1997	NULL
ABSTRACT	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
(	NULL
LMP1	NULL
)	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
transformation	NULL
of	NULL
B	NULL
lymphocytes	NULL
into	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
.	NULL

Previous	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
model	NULL
that	NULL
LMP1	NULL
is	NULL
a	NULL
constitutively	NULL
activated	NULL
receptor	NULL
that	NULL
transduces	NULL
signals	NULL
for	NULL
transformation	NULL
through	NULL
its	NULL
carboxyl-terminal	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

One	NULL
transformation	NULL
effector	NULL
site	NULL
(	NULL
TES1	NULL
)	NULL
,	NULL
located	NULL
within	NULL
the	NULL
membrane	NULL
proximal	NULL
45	NULL
residues	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
,	NULL
constitutively	NULL
engages	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
factors	NULL
.	NULL

Signals	NULL
from	NULL
TES1	NULL
are	NULL
sufficient	NULL
to	NULL
drive	NULL
initial	NULL
proliferation	NULL
of	NULL
infected	NULL
resting	NULL
B	NULL
lymphocytes	NULL
,	NULL
but	NULL
most	NULL
lymphoblastoid	NULL
cells	NULL
infected	NULL
with	NULL
a	NULL
virus	NULL
that	NULL
does	NULL
not	NULL
express	NULL
the	NULL
155	NULL
residues	NULL
beyond	NULL
TES1	NULL
fail	NULL
to	NULL
grow	NULL
as	NULL
long-term	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
now	NULL
find	NULL
that	NULL
mutating	NULL
two	NULL
tyrosines	NULL
to	NULL
an	NULL
isoleucine	NULL
at	NULL
the	NULL
carboxyl	NULL
end	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
cripples	NULL
the	NULL
ability	NULL
of	NULL
EBV	NULL
to	NULL
cause	NULL
lymphoblastoid	NULL
cell	NULL
outgrowth	NULL
,	NULL
thereby	NULL
marking	NULL
a	NULL
second	NULL
transformation	NULL
effector	NULL
site	NULL
,	NULL
TES2	NULL
.	NULL

A	NULL
yeast	NULL
two-hybrid	NULL
screen	NULL
identified	NULL
TES2	NULL
interacting	NULL
proteins	NULL
,	NULL
including	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor-associated	NULL
death	NULL
domain	NULL
protein	NULL
(	NULL
TRADD	NULL
)	NULL
.	NULL

TRADD	NULL
was	NULL
the	NULL
only	NULL
protein	NULL
that	NULL
interacted	NULL
with	NULL
wild-type	NULL
TES2	NULL
and	NULL
not	NULL
with	NULL
isoleucine-mutated	NULL
TES2	NULL
.	NULL

TRADD	NULL
associated	NULL
with	NULL
wild-type	NULL
LMP1	NULL
but	NULL
not	NULL
with	NULL
isoleucine-mutated	NULL
LMP	NULL
]	NULL
in	NULL
mammalian	NULL
cells	NULL
,	NULL
and	NULL
TRADD	NULL
constitutively	NULL
associated	NULL
with	NULL
LMP1	NULL
in	NULL
EBV-transformed	NULL
cells	NULL
.	NULL

In	NULL
transfection	NULL
assays	NULL
,	NULL
TRADD	NULL
and	NULL
TES2	NULL
synergistically	NULL
mediated	NULL
high-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
LMP1	NULL
appropriates	NULL
TRADD	NULL
to	NULL
enable	NULL
efficient	NULL
long-term	NULL
lymphoblastoid	NULL
cell	NULL
outgrowth	NULL
.	NULL

High-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
also	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
critical	NULL
component	NULL
of	NULL
long-term	NULL
outgrowth	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
infection	NULL
of	NULL
B	NULL
lymphocytes	NULL
is	NULL
nonpermissive	NULL
for	NULL
virus	NULL
replication	NULL
.	NULL

Instead	NULL
,	NULL
EBV	NULL
expresses	NULL
two	NULL
latent	NULL
membrane	NULL
proteins	NULL
(	NULL
LMPs	NULL
)	NULL
and	NULL
six	NULL
nuclear	NULL
pro-teins	NULL
.	NULL

These	NULL
proteins	NULL
efficiently	NULL
transform	NULL
resting	NULL
B	NULL
lymphocytes	NULL
into	NULL
continuously	NULL
proliferating	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCLs	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

1	NULL
)	NULL
.	NULL

LMP1	NULL
is	NULL
a	NULL
key	NULL
effector	NULL
of	NULL
EBV-mediated	NULL
transformation	NULL
.	NULL

LMP1	NULL
has	NULL
oncogene-like	NULL
activity	NULL
in	NULL
rodent	NULL
fibroblast	NULL
cell	NULL
lines	NULL
(	NULL
2-4	NULL
)	NULL
.	NULL

In	NULL
non-EBV-infected	NULL
B	NULL
lymphoma	NULL
cells	NULL
,	NULL
LMP1	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
induces	NULL
most	NULL
of	NULL
the	NULL
changes	NULL
associated	NULL
with	NULL
EBV	NULL
infection	NULL
,	NULL
including	NULL
up-regulated	NULL
expression	NULL
of	NULL
activation	NULL
mark-ers	NULL
,	NULL
adhesion	NULL
molecules	NULL
,	NULL
and	NULL
Bcl-2	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

In	NULL
epithelial	NULL
cells	NULL
,	NULL
LMP1	NULL
causes	NULL
hypertrophy	NULL
and	NULL
alters	NULL
differentiation	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

LMP1	NULL
is	NULL
essential	NULL
for	NULL
EBV	NULL
to	NULL
growth-transform	NULL
B	NULL
lymphocytes	NULL
into	NULL
LCLs	NULL
(	NULL
10	NULL
)	NULL
and	NULL
is	NULL
expressed	NULL
in	NULL
most	NULL
malignancies	NULL
associated	NULL
with	NULL
EBV	NULL
infection	NULL
,	NULL
including	NULL
lymphoproliferative	NULL
disease	NULL
,	NULL
Hodgkin	NULL
disease	NULL
,	NULL
and	NULL
nasopharyngeal	NULL
carcinoma	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

11	NULL
)	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
National	NULL
Academy	NULL
of	NULL
Sciences	NULL
0027-8424/97/9412592-6	NULL
$	NULL
2.00/0	NULL
PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
http	NULL
:	NULL
//www.pnas.org	NULL
.	NULL

12592	NULL
Recombinant	NULL
EBV	NULL
genetic	NULL
and	NULL
biochemical	NULL
analyses	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
model	NULL
that	NULL
LMP1	NULL
is	NULL
a	NULL
constitutively	NULL
activated	NULL
growth	NULL
factor	NULL
receptor	NULL
that	NULL
signals	NULL
through	NULL
its	NULL
cytoplasmic	NULL
carboxyl	NULL
terminus	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
six	NULL
transmembrane	NULL
domains	NULL
constitutively	NULL
aggregate	NULL
LMP1	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
without	NULL
exogenous	NULL
ligand	NULL
.	NULL

Aggregation	NULL
is	NULL
essential	NULL
for	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
(	NULL
10	NULL
,	NULL
12	NULL
)	NULL
.	NULL

The	NULL
six	NULL
transmembrane	NULL
domains	NULL
are	NULL
also	NULL
essential	NULL
for	NULL
oncogene-like	NULL
activity	NULL
in	NULL
rodent	NULL
fibroblast	NULL
cell	NULL
lines	NULL
and	NULL
phenotypic	NULL
changes	NULL
in	NULL
B	NULL
lymphoma	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
the	NULL
amino	NULL
and	NULL
carboxyl-terminal	NULL
cytoplasmic	NULL
tails	NULL
has	NULL
been	NULL
difficult	NULL
to	NULL
assess	NULL
in	NULL
rodent	NULL
fibroblast	NULL
transformation	NULL
assays	NULL
.	NULL

Some	NULL
assays	NULL
indicate	NULL
the	NULL
amino	NULL
terminus	NULL
is	NULL
important	NULL
for	NULL
transformation	NULL
(	NULL
13	NULL
)	NULL
whereas	NULL
others	NULL
implicate	NULL
the	NULL
carboxyl-terminal	NULL
tail	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
amino	NULL
terminus	NULL
is	NULL
not	NULL
an	NULL
effector	NULL
of	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
but	NULL
is	NULL
important	NULL
for	NULL
tethering	NULL
the	NULL
first	NULL
transmembrane	NULL
domain	NULL
to	NULL
the	NULL
cytoplasm	NULL
(	NULL
12	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
cytoplasmic	NULL
carboxyl	NULL
terminus	NULL
is	NULL
essential	NULL
for	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
and	NULL
therefore	NULL
is	NULL
implicated	NULL
in	NULL
signaling	NULL
(	NULL
15	NULL
)	NULL
.	NULL

One	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
effector	NULL
site	NULL
(	NULL
TES1	NULL
)	NULL
in	NULL
the	NULL
cytoplasmic	NULL
carboxyl	NULL
terminus	NULL
interacts	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
receptor	NULL
(	NULL
TNFR	NULL
)	NULL
signaling	NULL
pathways	NULL
.	NULL

The	NULL
first	NULL
evidence	NULL
for	NULL
TES1	NULL
was	NULL
from	NULL
EBV	NULL
recombinant	NULL
genetic	NULL
experiments	NULL
in	NULL
which	NULL
a	NULL
mutated	NULL
LMP1	NULL
MS231	NULL
was	NULL
sufficient	NULL
for	NULL
transforming	NULL
primary	NULL
B	NULL
lymphocytes	NULL
into	NULL
LCLs	NULL
that	NULL
required	NULL
fibroblast	NULL
feeder	NULL
cells	NULL
for	NULL
long-term	NULL
outgrowth	NULL
.	NULL

MS231	NULL
consists	NULL
of	NULL
the	NULL
amino	NULL
terminus	NULL
,	NULL
six	NULL
transmembrane	NULL
domains	NULL
,	NULL
and	NULL
membrane	NULL
proximal	NULL
45	NULL
residues	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Further	NULL
studies	NULL
of	NULL
MS231	NULL
recombinant	NULL
virus	NULL
revealed	NULL
that	NULL
infected	NULL
cells	NULL
proliferate	NULL
for	NULL
several	NULL
weeks	NULL
,	NULL
but	NULL
thereafter	NULL
most	NULL
of	NULL
these	NULL
cells	NULL
replicate	NULL
progressively	NULL
more	NULL
slowly	NULL
and	NULL
then	NULL
die	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
nearly	NULL
all	NULL
wild-type	NULL
EBV-transformed	NULL
LCLs	NULL
are	NULL
immortal	NULL
(	NULL
K.M	NULL
.	NULL

Kaye	NULL
,	NULL
KL	NULL
,	NULL
E.	NULL
Johanssen	NULL
,	NULL
and	NULL
EK	NULL
.	NULL

,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

TES1	NULL
was	NULL
delineated	NULL
as	NULL
a	NULL
potential	NULL
signaling	NULL
motif	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
residues	NULL
within	NULL
the	NULL
membrane	NULL
proximal	NULL
45	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
engage	NULL
TNFR-associated	NULL
factors	NULL
(	NULL
TRAFs	NULL
)	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
TRAF	NULL
binding	NULL
site	NULL
results	NULL
in	NULL
a	NULL
nontransforming	NULL
EBV	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
LCLs	NULL
,	NULL
LMP1	NULL
is	NULL
constitutively	NULL
associated	NULL
with	NULL
TRAF3	NULL
and	NULL
TRAF1	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
with	NULL
TRAF2	NULL
(	NULL
18	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TRAFs	NULL
are	NULL
recruited	NULL
to	NULL
TNFR2	NULL
or	NULL
to	NULL
TNFR	NULL
family	NULL
members	NULL
such	NULL
as	NULL
CD40	NULL
and	NULL
LTB	NULL
receptor	NULL
in	NULL
response	NULL
to	NULL
ligand	NULL
binding	NULL
and	NULL
receptor	NULL
aggregation	NULL
(	NULL
19-21	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
mimicry	NULL
of	NULL
an	NULL
activated	NULL
TNFR	NULL
is	NULL
concordant	NULL
with	NULL
the	NULL
similar	NULL
effects	NULL
of	NULL
LMP1	NULL
and	NULL
activated	NULL
CD40	NULL
on	NULL
B	NULL
lymphocyte	NULL
growth	NULL
and	NULL
gene	NULL
activation	NULL
(	NULL
18	NULL
,	NULL
21-26	NULL
)	NULL
.	NULL

Abbreviations	NULL
:	NULL
EBV	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
;	NULL
LMP	NULL
,	NULL
latent	NULL
membrane	NULL
protein	NULL
;	NULL
LCLs	NULL
,	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
TNFR	NULL
,	NULL
TNF	NULL
receptor	NULL
;	NULL
TRADD	NULL
,	NULL
TNF	NULL
receptor-associated	NULL
death	NULL
do	NULL
main	NULL
;	NULL
TRAF	NULL
,	NULL
TNF	NULL
receptor-associated	NULL
factor	NULL
;	NULL
TES	NULL
,	NULL
transformation	NULL
effector	NULL
site	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

e-mail	NULL
:	NULL
ekieff	NULL
@	NULL
rics	NULL
.	NULL

bwh.harvard.edu	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Izumi	NULL
and	NULL
Kieff	NULL
Drives	NULL
initial	NULL
cell	NULL
proliferation	NULL
TRAF3,1	NULL
,	NULL
&	NULL
2	NULL
association	NULL
Low	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
Enables	NULL
efficient	NULL
long-term	NULL
LCL	NULL
outgrowth	NULL
TRADD	NULL
association	NULL
High	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Diagram	NULL
of	NULL
LMP1	NULL
.	NULL

The	NULL
Flag	NULL
epitope	NULL
was	NULL
introduced	NULL
at	NULL
the	NULL
amino	NULL
terminus	NULL
(	NULL
NH	NULL
;	NULL
)	NULL
.	NULL

LMP1	NULL
residues	NULL
187	NULL
,	NULL
231	NULL
,	NULL
352	NULL
,	NULL
and	NULL
386	NULL
are	NULL
noted	NULL
.	NULL

LMP1	NULL
constitutively	NULL
aggregates	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
.	NULL

TES1	NULL
engages	NULL
TR	NULL
AFs	NULL
to	NULL
drive	NULL
initial	NULL
B	NULL
lymphocyte	NULL
proliferation	NULL
and	NULL
induce	NULL
low-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

TES2	NULL
engages	NULL
TRADD	NULL
to	NULL
enable	NULL
efficient	NULL
long-term	NULL
lymphoblastoid	NULL
cell	NULL
outgrowth	NULL
and	NULL
mediate	NULL
high-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
through	NULL
TRAF2	NULL
.	NULL

Because	NULL
EBV	NULL
recombinants	NULL
that	NULL
express	NULL
only	NULL
TES1	NULL
are	NULL
functionally	NULL
impaired	NULL
in	NULL
causing	NULL
LCL	NULL
outgrowth	NULL
,	NULL
the	NULL
objective	NULL
of	NULL
these	NULL
experiments	NULL
was	NULL
to	NULL
define	NULL
the	NULL
role	NULL
of	NULL
the	NULL
membrane	NULL
distal	NULL
155	NULL
residues	NULL
beyond	NULL
TES1	NULL
in	NULL
enabling	NULL
efficient	NULL
,	NULL
long-term	NULL
LCL	NULL
outgrowth	NULL
.	NULL

Potentially	NULL
relevant	NULL
to	NULL
the	NULL
role	NULL
of	NULL
these	NULL
residues	NULL
in	NULL
transformation	NULL
are	NULL
previous	NULL
findings	NULL
that	NULL
TES1	NULL
mediates	NULL
only	NULL
25	NULL
%	NULL
of	NULL
LMP1-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
whereas	NULL
75	NULL
%	NULL
maps	NULL
to	NULL
the	NULL
terminal	NULL
55	NULL
or	NULL
35	NULL
residues	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

NF-KB	NULL
activation	NULL
correlates	NULL
with	NULL
lymphocyte	NULL
activation	NULL
,	NULL
and	NULL
high-level	NULL
NF-kB	NULL
activation	NULL
could	NULL
be	NULL
important	NULL
in	NULL
EBV-mediated	NULL
transformation	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

TRAF1	NULL
and	NULL
TRAF2	NULL
dimers	NULL
are	NULL
implicated	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
from	NULL
TES1	NULL
,	NULL
and	NULL
NF-kB	NULL
activation	NULL
by	NULL
TES1	NULL
was	NULL
more	NULL
than	NULL
75	NULL
%	NULL
blocked	NULL
by	NULL
a	NULL
dominant	NULL
negative	NULL
TRAF	NULL
?	NULL

(	NULL
18	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Yet	NULL
,	NULL
despite	NULL
similarities	NULL
to	NULL
a	NULL
TRAF	NULL
binding	NULL
site	NULL
within	NULL
the	NULL
terminal	NULL
55	NULL
residues	NULL
of	NULL
LMP1	NULL
,	NULL
TRAF	NULL
1	NULL
,	NULL
2	NULL
,	NULL
or	NULL
3	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
carboxyl-terminal	NULL
155	NULL
residues	NULL
,	NULL
and	NULL
a	NULL
dominant	NULL
negative	NULL
TRAF2	NULL
only	NULL
partially	NULL
blocked	NULL
NF-kB	NULL
activation	NULL
by	NULL
the	NULL
last	NULL
55	NULL
residues	NULL
(	NULL
17	NULL
,	NULL
18	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
neither	NULL
the	NULL
significance	NULL
nor	NULL
the	NULL
mechanism	NULL
of	NULL
high-level	NULL
NF-KB	NULL
activation	NULL
was	NULL
evident	NULL
at	NULL
the	NULL
start	NULL
of	NULL
these	NULL
studies	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Viruses	NULL
,	NULL
Cells	NULL
,	NULL
and	NULL
DNA	NULL
Clones	NULL
.	NULL

Viruses	NULL
and	NULL
cell	NULL
lines	NULL
were	NULL
grown	NULL
as	NULL
described	NULL
(	NULL
12	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Vectors	NULL
pRK-mycTRADD	NULL
and	NULL
pRK5	NULL
were	NULL
gifts	NULL
from	NULL
David	NULL
Goeddel	NULL
(	NULL
Tularik	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
(	NULL
32	NULL
)	NULL
.	NULL

F-LMP1-ID	NULL
and	NULL
F-LMP1-FFD	NULL
DNAs	NULL
and	NULL
expression	NULL
vectors	NULL
are	NULL
derived	NULL
by	NULL
endonuclease	NULL
deletion	NULL
or	NULL
codon	NULL
insertions	NULL
into	NULL
F-LMP1	NULL
as	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Recombinant	NULL
EBV	NULL
Construction	NULL
and	NULL
Characterization	NULL
.	NULL

EBV	NULL
recombinants	NULL
were	NULL
generated	NULL
by	NULL
second-site	NULL
homologous	NULL
recombination	NULL
in	NULL
P3HR-1	NULL
cells	NULL
,	NULL
tested	NULL
in	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
assays	NULL
,	NULL
and	NULL
characterized	NULL
as	NULL
described	NULL
(	NULL
12	NULL
,	NULL
17	NULL
,	NULL
33-35	NULL
)	NULL
.	NULL

Yeast	NULL
Two-Hybrid	NULL
Assay	NULL
.	NULL

The	NULL
methods	NULL
of	NULL
yeast	NULL
culture	NULL
,	NULL
transformation	NULL
,	NULL
and	NULL
B-galactosidase	NULL
detection	NULL
were	NULL
as	NULL
described	NULL
(	NULL
36	NULL
)	NULL
.	NULL

GAL-DBD-LMP1	NULL
fusions	NULL
are	NULL
derived	NULL
from	NULL
FLMP1	NULL
clones	NULL
(	NULL
above	NULL
)	NULL
or	NULL
as	NULL
before	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Coimmune	NULL
Precipitation	NULL
Analyses	NULL
.	NULL

Precipitations	NULL
with	NULL
M2	NULL
affinity	NULL
gel	NULL
(	NULL
Kodak	NULL
)	NULL
were	NULL
as	NULL
described	NULL
except	NULL
that	NULL
TRADD	NULL
antisera	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
or	NULL
9E10	NULL
antibody	NULL
to	NULL
mye	NULL
were	NULL
used	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
-	NULL
12593	NULL
NF-B	NULL
Activation	NULL
.	NULL

3	NULL
%	NULL
-	NULL
«	NULL
B-L	NULL
luciferase	NULL
reporter	NULL
and	NULL
mut-	NULL
«	NULL
B-L	NULL
control	NULL
were	NULL
gifts	NULL
from	NULL
Bill	NULL
Sugden	NULL
(	NULL
University	NULL
of	NULL
Wisconsin	NULL
at	NULL
Madison	NULL
)	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Methods	NULL
were	NULL
as	NULL
described	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

RESULTS	NULL
The	NULL
Last	NULL
Three	NULL
Residues	NULL
of	NULL
LMP1	NULL
Are	NULL
Critical	NULL
for	NULL
Primary	NULL
B	NULL
Lymphocyte	NULL
Growth	NULL
Transformation	NULL
.	NULL

To	NULL
identify	NULL
a	NULL
site	NULL
in	NULL
the	NULL
carboxyl-terminal	NULL
155	NULL
residues	NULL
that	NULL
is	NULL
critical	NULL
in	NULL
enabling	NULL
efficient	NULL
,	NULL
long-term	NULL
LCL	NULL
outgrowth	NULL
,	NULL
two	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
last	NULL
three	NULL
carboxyl-terminal	NULL
residues	NULL
and	NULL
a	NULL
series	NULL
of	NULL
incremental	NULL
deletions	NULL
were	NULL
constructed	NULL
in	NULL
an	NULL
LMP1	NULL
gene	NULL
that	NULL
has	NULL
a	NULL
Flag	NULL
epitope	NULL
insertion	NULL
at	NULL
the	NULL
amino	NULL
terminus	NULL
(	NULL
F-LMP1	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
last	NULL
three	NULL
carboxyl-terminal	NULL
amino	NULL
acids	NULL
of	NULL
LMP1	NULL
are	NULL
YYD	NULL
,	NULL
and	NULL
the	NULL
two	NULL
point	NULL
mutations	NULL
were	NULL
YYD	NULL
to	NULL
FFD	NULL
or	NULL
YYD	NULL
to	NULL
ID	NULL
.	NULL

The	NULL
method	NULL
of	NULL
P3HR-1	NULL
second	NULL
site	NULL
homologous	NULL
recombination	NULL
was	NULL
used	NULL
to	NULL
introduce	NULL
the	NULL
point	NULL
mutations	NULL
and	NULL
series	NULL
of	NULL
incremental	NULL
deletions	NULL
into	NULL
complete	NULL
EBV	NULL
genomes	NULL
(	NULL
17	NULL
,	NULL
33	NULL
,	NULL
34	NULL
,	NULL
37-39	NULL
)	NULL
.	NULL

The	NULL
P3HR-1	NULL
EBV	NULL
is	NULL
replication	NULL
competent	NULL
but	NULL
transformation	NULL
defective	NULL
because	NULL
of	NULL
a	NULL
deletion	NULL
.	NULL

This	NULL
deletion	NULL
can	NULL
be	NULL
rescued	NULL
by	NULL
transfecting	NULL
P3HR-1	NULL
EBV-infected	NULL
cells	NULL
with	NULL
DNA	NULL
that	NULL
spans	NULL
the	NULL
deletion	NULL
site	NULL
.	NULL

Recombinants	NULL
then	NULL
can	NULL
be	NULL
recovered	NULL
because	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
growth	NULL
transform	NULL
B	NULL
lymphocytes	NULL
into	NULL
LCLs	NULL
.	NULL

Cotransfecting	NULL
P3HR-1-infected	NULL
cells	NULL
with	NULL
the	NULL
rescuing	NULL
DNA	NULL
fragment	NULL
and	NULL
a	NULL
second	NULL
EBV	NULL
DNA	NULL
fragment	NULL
results	NULL
in	NULL
incorporation	NULL
of	NULL
the	NULL
second	NULL
DNA	NULL
fragment	NULL
into	NULL
10	NULL
%	NULL
of	NULL
the	NULL
rescued	NULL
EBV	NULL
genomes	NULL
.	NULL

Consistent	NULL
with	NULL
predicted	NULL
results	NULL
,	NULL
FLMP1	NULL
recombinants	NULL
were	NULL
recovered	NULL
in	NULL
14	NULL
%	NULL
(	NULL
31	NULL
of	NULL
233	NULL
)	NULL
of	NULL
the	NULL
LCL	NULL
s	NULL
,	NULL
and	NULL
F-LMP1-FFD	NULL
recombinants	NULL
were	NULL
recovered	NULL
in	NULL
8	NULL
%	NULL
(	NULL
20	NULL
of	NULL
243	NULL
)	NULL
of	NULL
the	NULL
LCL	NULL
s.	NULL
In	NULL
contrast	NULL
,	NULL
F-LMP1-ID	NULL
recombinants	NULL
were	NULL
recovered	NULL
in	NULL
only	NULL
3	NULL
%	NULL
(	NULL
13	NULL
of	NULL
458	NULL
)	NULL
of	NULL
the	NULL
LCLs	NULL
.	NULL

Recombinants	NULL
with	NULL
more	NULL
severe	NULL
carboxyl-terminal	NULL
deletions	NULL
also	NULL
were	NULL
recovered	NULL
in	NULL
fewer	NULL
LCLs	NULL
than	NULL
the	NULL
predicted	NULL
10	NULL
%	NULL
.	NULL

All	NULL
LCLs	NULL
except	NULL
for	NULL
one	NULL
infected	NULL
with	NULL
an	NULL
F-LMP1-FFD	NULL
recombinant	NULL
were	NULL
coinfected	NULL
with	NULL
P3HR-1	NULL
EBV	NULL
.	NULL

Because	NULL
the	NULL
low	NULL
percentage	NULL
of	NULL
F-LMP1-ID-infected	NULL
LCLs	NULL
appeared	NULL
to	NULL
define	NULL
a	NULL
site	NULL
important	NULL
in	NULL
transformation	NULL
,	NULL
we	NULL
put	NULL
aside	NULL
the	NULL
series	NULL
of	NULL
deletion	NULL
mutations	NULL
and	NULL
focused	NULL
on	NULL
characterizing	NULL
the	NULL
transformation	NULL
phenotypes	NULL
of	NULL
F-LMP-ID	NULL
and	NULL
F-LMP-FFD	NULL
recombinants	NULL
by	NULL
comparing	NULL
them	NULL
with	NULL
control	NULL
F-LMP1	NULL
recombinants	NULL
.	NULL

Virus	NULL
from	NULL
four	NULL
independently	NULL
derived	NULL
LCLs	NULL
that	NULL
were	NULL
coinfected	NULL
with	NULL
an	NULL
F-LMP1-ID	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
and	NULL
from	NULL
two	NULL
independently	NULL
derived	NULL
LCLs	NULL
that	NULL
were	NULL
coinfected	NULL
with	NULL
an	NULL
F-LMP1	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
was	NULL
passaged	NULL
onto	NULL
primary	NULL
B	NULL
lymphocytes	NULL
.	NULL

Virus	NULL
from	NULL
the	NULL
LCL	NULL
infected	NULL
with	NULL
an	NULL
F-LMP1-FFD	NULL
recombinant	NULL
without	NULL
P3HR-1	NULL
also	NULL
was	NULL
passaged	NULL
to	NULL
verify	NULL
that	NULL
this	NULL
recombinant	NULL
is	NULL
wild	NULL
type	NULL
for	NULL
replication	NULL
and	NULL
growth	NULL
transformation	NULL
.	NULL

By	NULL
PCR	NULL
analysis	NULL
,	NULL
virus	NULL
preparations	NULL
from	NULL
the	NULL
respective	NULL
coinfected	NULL
LCLs	NULL
contained	NULL
nearly	NULL
equimolar	NULL
amounts	NULL
of	NULL
F-LMP1-ID	NULL
DNA	NULL
and	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
or	NULL
nearly	NULL
equimolar	NULL
amounts	NULL
of	NULL
F-LMP1	NULL
DNA	NULL
and	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Hundreds	NULL
of	NULL
B	NULL
lymphocytes	NULL
were	NULL
transformed	NULL
with	NULL
these	NULL
virus	NULL
preparations	NULL
,	NULL
and	NULL
these	NULL
LCLs	NULL
were	NULL
analyzed	NULL
for	NULL
EBV	NULL
genotypes	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
Table	NULL
1	NULL
were	NULL
that	NULL
F-LMP1-ID	NULL
recombinants	NULL
were	NULL
recovered	NULL
in	NULL
116	NULL
LCLs	NULL
,	NULL
and	NULL
in	NULL
every	NULL
instance	NULL
the	NULL
LCLs	NULL
were	NULL
coinfected	NULL
with	NULL
P3HR-1	NULL
EBV	NULL
.	NULL

Infection	NULL
of	NULL
B	NULL
lymphocytes	NULL
with	NULL
less	NULL
input	NULL
virus	NULL
reduces	NULL
the	NULL
number	NULL
of	NULL
LCLs	NULL
and	NULL
increases	NULL
the	NULL
probability	NULL
of	NULL
clonally	NULL
segregating	NULL
a	NULL
transforming	NULL
recombinant	NULL
from	NULL
P3HR-1	NULL
EBV	NULL
,	NULL
but	NULL
none	NULL
of	NULL
the	NULL
41	NULL
LCLs	NULL
that	NULL
were	NULL
obtained	NULL
after	NULL
infection	NULL
with	NULL
less	NULL
input	NULL
virus	NULL
were	NULL
infected	NULL
with	NULL
an	NULL
F-LMP1-ID	NULL
recombinant	NULL
only	NULL
.	NULL

Overall	NULL
,	NULL
more	NULL
LCLs	NULL
(	NULL
157	NULL
)	NULL
were	NULL
transformed	NULL
by	NULL
secondary	NULL
recombinants	NULL
that	NULL
have	NULL
complete	NULL
genomes	NULL
with	NULL
the	NULL
P3HR-1	NULL
LMP1	NULL
gene	NULL
in	NULL
place	NULL
of	NULL
the	NULL
F-LMP1-ID	NULL
gene	NULL
.	NULL

Given	NULL
the	NULL
nearly	NULL
equal	NULL
molarity	NULL
of	NULL
the	NULL
F-LMP1-ID	NULL
DNA	NULL
and	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
in	NULL
the	NULL
virus	NULL
preparations	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
a	NULL
strong	NULL
preference	NULL
for	NULL
the	NULL
P3HR-1	NULL
LMP1	NULL
gene	NULL
in	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

Clonal	NULL
transformation	NULL
assay	NULL
of	NULL
virus	NULL
preparations	NULL
containing	NULL
F-LMP1	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
EBV	NULL
produced	NULL
contrasting	NULL
results	NULL
.	NULL

More	NULL
than	NULL
half	NULL
of	NULL
the	NULL
resultant	NULL
LCL	NULL
s	NULL
(	NULL
27	NULL
of	NULL
51	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
12594	NULL
-	NULL
Medical	NULL
Sciences	NULL
:	NULL
Izumi	NULL
and	NULL
Kieff	NULL
Table	NULL
1	NULL
.	NULL

B	NULL
lymphocyte	NULL
transformation	NULL
by	NULL
EBV	NULL
recombinants	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
%	NULL
infected	NULL
Number	NULL
of	NULL
resultant	NULL
LCLs	NULL
with	NULL
:	NULL
Original	NULL
LCL	NULL
Viral	NULL
genomes	NULL
in	NULL
wells	NULL
with	NULL
F-LMP1	NULL
F-LMP1	NULL
&	NULL
P3HR-1	NULL
source	NULL
of	NULL
virus	NULL
original	NULL
LCLs	NULL
LCLs	NULL
alone	NULL
P3HR-1	NULL
LMP1	NULL
LMP1	NULL
alone	NULL
F-LMP1-1	NULL
F-LMP1	NULL
&	NULL
P3HR-1	NULL
17	NULL
8	NULL
7	NULL
16	NULL
1	NULL
1	NULL
0	NULL
1	NULL
F-LMP1-2	NULL
F-LMP1	NULL
&	NULL
P3HR-1	NULL
9	NULL
17	NULL
0	NULL
0	NULL
1	NULL
1	NULL
0	NULL
0	NULL
F-LMP1-ID-1	NULL
F-LMP1-ID	NULL
&	NULL
P3HR-1	NULL
19	NULL
0	NULL
86	NULL
8	NULL
2	NULL
0	NULL
19	NULL
2	NULL
F-LMP1-ID-2	NULL
F-LMP1-ID	NULL
&	NULL
P3HR-1	NULL
100	NULL
0	NULL
10	NULL
85	NULL
5	NULL
0	NULL
1	NULL
19	NULL
F-LMP1-ID-3	NULL
F-LMP1-ID	NULL
&	NULL
P3HR-1	NULL
11	NULL
0	NULL
0	NULL
14	NULL
F-LMP1-ID-4	NULL
F-LMP1-ID	NULL
&	NULL
P3HR-1	NULL
15	NULL
0	NULL
0	NULL
29	NULL
F-LMP1-FFD-1	NULL
F-LMP1-FFD	NULL
38	NULL
48	NULL
0	NULL
0	NULL
Virus	NULL
replication	NULL
was	NULL
induced	NULL
in	NULL
EBV-infected	NULL
LCLs	NULL
(	NULL
column	NULL
1	NULL
)	NULL
.	NULL

B	NULL
lymphocytes	NULL
were	NULL
infected	NULL
with	NULL
dilutions	NULL
of	NULL
the	NULL
resultant	NULL
viruses	NULL
(	NULL
column	NULL
2	NULL
)	NULL
and	NULL
seeded	NULL
into	NULL
96-well	NULL
plates	NULL
.	NULL

If	NULL
the	NULL
percentage	NULL
of	NULL
wells	NULL
with	NULL
LCLs	NULL
(	NULL
column	NULL
3	NULL
)	NULL
is	NULL
less	NULL
than	NULL
40	NULL
%	NULL
,	NULL
P3HR-1	NULL
usually	NULL
is	NULL
segregated	NULL
from	NULL
a	NULL
transforming	NULL
recombinant	NULL
.	NULL

LCLs	NULL
that	NULL
are	NULL
infected	NULL
with	NULL
a	NULL
recombinant	NULL
alone	NULL
(	NULL
column	NULL
4	NULL
)	NULL
are	NULL
positive	NULL
for	NULL
F-LMP1	NULL
DNA	NULL
and	NULL
negative	NULL
for	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
.	NULL

LCLs	NULL
coinfected	NULL
with	NULL
a	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
(	NULL
column	NULL
5	NULL
)	NULL
are	NULL
positive	NULL
for	NULL
both	NULL
F-LMP1	NULL
and	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
.	NULL

Secondary	NULL
recombinant	NULL
transformed	NULL
LCLs	NULL
(	NULL
column	NULL
6	NULL
)	NULL
are	NULL
infected	NULL
with	NULL
a	NULL
transforming	NULL
EBV	NULL
that	NULL
has	NULL
only	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
.	NULL

an	NULL
F-LMP1	NULL
EBV	NULL
recombinant	NULL
without	NULL
P3HR-1	NULL
EBV	NULL
,	NULL
17	NULL
of	NULL
51	NULL
were	NULL
infected	NULL
with	NULL
a	NULL
secondary	NULL
recombinant	NULL
that	NULL
had	NULL
the	NULL
P3HR-1	NULL
LMP1	NULL
in	NULL
place	NULL
of	NULL
F-LMP1	NULL
,	NULL
and	NULL
7	NULL
of	NULL
51	NULL
were	NULL
coinfected	NULL
with	NULL
an	NULL
F-LMP1	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
EBV	NULL
.	NULL

Because	NULL
no	NULL
P3HR-1	NULL
EBV	NULL
was	NULL
in	NULL
the	NULL
F-LMP1-FFD	NULL
recombinant	NULL
virus	NULL
preparation	NULL
,	NULL
48	NULL
of	NULL
48	NULL
LCL	NULL
s	NULL
were	NULL
transformed	NULL
by	NULL
F-LMP1-FFD	NULL
recombinant	NULL
.	NULL

The	NULL
F-LMP1-infected	NULL
LCLs	NULL
that	NULL
lacked	NULL
P3HR-1	NULL
LMP1	NULL
on	NULL
initial	NULL
PCR	NULL
screening	NULL
and	NULL
all	NULL
of	NULL
the	NULL
F-LMP1-FFD-infected	NULL
LCL	NULL
s	NULL
were	NULL
retested	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
P3HR-1	NULL
EBV	NULL
by	NULL
using	NULL
a	NULL
PCR	NULL
method	NULL
that	NULL
specifically	NULL
detects	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
LCLs	NULL
had	NULL
less	NULL
than	NULL
the	NULL
assay	NULL
limit	NULL
of	NULL
four	NULL
copies	NULL
of	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
per	NULL
10,000	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
summarize	NULL
these	NULL
results	NULL
,	NULL
F-LMP1	NULL
and	NULL
F-LMP1-FFD	NULL
recombinants	NULL
are	NULL
able	NULL
to	NULL
transform	NULL
B	NULL
lymphocytes	NULL
into	NULL
LCLs	NULL
without	NULL
P3HR-1	NULL
EBV	NULL
whereas	NULL
F-LMP1-ID	NULL
recombinants	NULL
can	NULL
not	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
YYD	NULL
to	NULL
ID	NULL
mutation	NULL
defines	NULL
a	NULL
second	NULL
effector	NULL
site	NULL
that	NULL
is	NULL
critical	NULL
for	NULL
transforming	NULL
B	NULL
lymphocytes	NULL
into	NULL
LCLs	NULL
capable	NULL
of	NULL
long-term	NULL
outgrowth	NULL
.	NULL

The	NULL
LMP1	NULL
genes	NULL
in	NULL
LCL	NULL
s	NULL
coinfected	NULL
with	NULL
F-LMP1-ID	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
and	NULL
in	NULL
LCLs	NULL
infected	NULL
with	NULL
F-LMP1	NULL
or	NULL
F-LMP1-FFD	NULL
recombinants	NULL
were	NULL
confirmed	NULL
to	NULL
have	NULL
recombined	NULL
homologously	NULL
by	NULL
Southern	NULL
blot	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
and	NULL
PCR	NULL
analyses	NULL
(	NULL
12	NULL
,	NULL
17	NULL
)	NULL
.	NULL

DNA	NULL
extracted	NULL
from	NULL
LCLs	NULL
was	NULL
cut	NULL
with	NULL
MiuI	NULL
and	NULL
SacI	NULL
and	NULL
Southern	NULL
blot-hybridized	NULL
with	NULL
a	NULL
wild-type	NULL
2.4-kb	NULL
LMP1	NULL
DNA	NULL
probe	NULL
.	NULL

P3HR-1	NULL
LMP1	NULL
DNA	NULL
was	NULL
identified	NULL
by	NULL
a	NULL
characteristic	NULL
2	NULL
4-kb	NULL
DNA	NULL
,	NULL
F-LMP1	NULL
recombinant	NULL
DNA	NULL
by	NULL
a	NULL
2.3-kb	NULL
DNA	NULL
because	NULL
of	NULL
a	NULL
SacI	NULL
site	NULL
at	NULL
the	NULL
Flag	NULL
codon	NULL
insertion	NULL
,	NULL
and	NULL
F-LMP1-FFD	NULL
or	NULL
F-LMP1-ID	NULL
recombinant	NULL
DNA	NULL
by	NULL
1.2-	NULL
and	NULL
1.1-kb	NULL
DNAs	NULL
because	NULL
of	NULL
a	NULL
second	NULL
SacI	NULL
site	NULL
near	NULL
the	NULL
site	NULL
of	NULL
the	NULL
FFD	NULL
or	NULL
ID	NULL
mutations	NULL
.	NULL

In	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
PCR	NULL
with	NULL
one	NULL
primer	NULL
specific	NULL
for	NULL
LMP1	NULL
exon	NULL
1	NULL
and	NULL
a	NULL
second	NULL
primer	NULL
anchored	NULL
in	NULL
the	NULL
EBV	NULL
terminal	NULL
repeat	NULL
but	NULL
ending	NULL
in	NULL
the	NULL
adjacent	NULL
unique	NULL
DNA	NULL
confirmed	NULL
that	NULL
the	NULL
F-LMP1	NULL
,	NULL
F-LMP1-ID	NULL
,	NULL
F-LMP1-FFD	NULL
,	NULL
and	NULL
P3HR-1	NULL
LMP1	NULL
DNAs	NULL
were	NULL
separated	NULL
by	NULL
the	NULL
expected	NULL
number	NULL
of	NULL
base	NULL
pairs	NULL
from	NULL
the	NULL
right	NULL
end	NULL
terminal	NULL
repeat	NULL
.	NULL

P3HR1	NULL
EBV	NULL
LMP1	NULL
DNA	NULL
yielded	NULL
an	NULL
880-bp	NULL
DNA	NULL
that	NULL
was	NULL
not	NULL
cut	NULL
with	NULL
Sacl	NULL
whereas	NULL
F-LMP1	NULL
,	NULL
F-LMP1-ID	NULL
,	NULL
and	NULL
F-LMP1-FFD	NULL
recombinant	NULL
DNA	NULL
produced	NULL
908-bp	NULL
DNAs	NULL
that	NULL
were	NULL
cut	NULL
with	NULL
SacI	NULL
to	NULL
yield	NULL
the	NULL
expected	NULL
189-and	NULL
719-bp	NULL
DNAs	NULL
.	NULL

F-LMP1-ID	NULL
recombinant	NULL
and	NULL
P3HR-1	NULL
coinfected	NULL
LCLs	NULL
also	NULL
were	NULL
confirmed	NULL
to	NULL
express	NULL
F-LMP1-ID	NULL
by	NULL
immunoblot	NULL
and	NULL
by	NULL
immunofluorescence	NULL
with	NULL
antibody	NULL
to	NULL
Flag	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
Western	NULL
immunoblots	NULL
revealed	NULL
similar	NULL
levels	NULL
of	NULL
a	NULL
60-kDa	NULL
Flag-LMP1	NULL
(	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
)	NULL
in	NULL
lysates	NULL
from	NULL
LCLs	NULL
infected	NULL
with	NULL
F-LMP1	NULL
,	NULL
F-LMP1-FFD	NULL
,	NULL
or	NULL
F-LMP1-ID	NULL
EBV	NULL
recombinants	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
immunofluorescent	NULL
staining	NULL
with	NULL
antibody	NULL
to	NULL
Flag	NULL
revealed	NULL
F-LMP1-ID	NULL
(	NULL
C1	NULL
)	NULL
and	NULL
F-LMP1	NULL
(	NULL
C2	NULL
)	NULL
were	NULL
in	NULL
plasma	NULL
membrane	NULL
aggregates	NULL
indistinguishable	NULL
from	NULL
wild-type	NULL
LMP1	NULL
.	NULL

Flag	NULL
antibody	NULL
does	NULL
not	NULL
detect	NULL
LMP1	NULL
in	NULL
P3HR-1	NULL
cells	NULL
(	NULL
C3	NULL
)	NULL
or	NULL
in	NULL
a	NULL
wild-type	NULL
EBV-transformed	NULL
LCL	NULL
(	NULL
C4	NULL
)	NULL
.	NULL

As	NULL
ex-pected	NULL
,	NULL
$	NULL
12	NULL
antibody	NULL
to	NULL
the	NULL
LMP1	NULL
repetitive	NULL
motif	NULL
detected	NULL
LMP1	NULL
in	NULL
plasma	NULL
membrane	NULL
aggregates	NULL
in	NULL
all	NULL
four	NULL
LCLs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
;	NULL
ref	NULL
.	NULL

40	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
inability	NULL
of	NULL
F-LMP1-ID	NULL
recombinants	NULL
to	NULL
growth	NULL
transform	NULL
B	NULL
lymphocytes	NULL
is	NULL
not	NULL
caused	NULL
by	NULL
protein	NULL
instability	NULL
or	NULL
aberrant	NULL
localization	NULL
.	NULL

In	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
F-LMP1-ID	NULL
aggregated	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
in	NULL
transfected	NULL
B	NULL
lymphoma	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
its	NULL
aggregation	NULL
is	NULL
not	NULL
dependent	NULL
on	NULL
wild-type	NULL
LMP1	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
failure	NULL
of	NULL
F-LMP1-ID	NULL
recombinants	NULL
to	NULL
transform	NULL
cells	NULL
without	NULL
wild-type	NULL
LMP1	NULL
likely	NULL
is	NULL
caused	NULL
by	NULL
mutation	NULL
of	NULL
an	NULL
effector	NULL
site	NULL
rather	NULL
than	NULL
a	NULL
global	NULL
effect	NULL
on	NULL
protein	NULL
stability	NULL
or	NULL
localization	NULL
.	NULL

We	NULL
therefore	NULL
designate	NULL
the	NULL
two	NULL
tyrosines	NULL
to	NULL
be	NULL
a	NULL
principal	NULL
component	NULL
of	NULL
TES2	NULL
.	NULL

TRADD	NULL
Is	NULL
Unique	NULL
Among	NULL
Interacting	NULL
Proteins	NULL
in	NULL
Specificity	NULL
for	NULL
Wild-Type	NULL
TES2	NULL
.	NULL

We	NULL
used	NULL
a	NULL
yeast	NULL
two-hybrid	NULL
screen	NULL
to	NULL
search	NULL
for	NULL
a	NULL
cell	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
that	NULL
interacts	NULL
with	NULL
F-LMP1	NULL
but	NULL
not	NULL
with	NULL
F-LMP1-ID	NULL
.	NULL

LMP1	NULL
codons	NULL
355-386	NULL
fused	NULL
to	NULL
the	NULL
GAL4	NULL
DNA	NULL
binding	NULL
domain	NULL
(	NULL
GALA4-DBD	NULL
)	NULL
were	NULL
used	NULL
as	NULL
bait	NULL
to	NULL
trap	NULL
cDNA	NULL
library	NULL
prey	NULL
fused	NULL
to	NULL
the	NULL
GALA	NULL
activating	NULL
domain	NULL
(	NULL
GALA-AD	NULL
)	NULL
(	NULL
36	NULL
)	NULL
.	NULL

From	NULL
17	NULL
million	NULL
yeast	NULL
transformed	NULL
with	NULL
GAL4-DBD-LMP1	NULL
(	NULL
355-386	NULL
)	NULL
bait	NULL
and	NULL
GALA-AD-cDNA	NULL
prey	NULL
,	NULL
19	NULL
interacting	NULL
cDNAs	NULL
were	NULL
identified	NULL
by	NULL
activation	NULL
of	NULL
GAL4	NULL
responsive	NULL
histi-dine	NULL
biosynthesis	NULL
and	NULL
B-galactosidase	NULL
production	NULL
.	NULL

The	NULL
cDNAs	NULL
were	NULL
the	NULL
aspartate	NULL
transcarbamalase	NULL
component	NULL
of	NULL
dihydrooro-tase	NULL
(	NULL
four	NULL
times	NULL
)	NULL
,	NULL
glucosidase	NULL
I	NULL
,	NULL
an	NULL
X-linked	NULL
nuclear	NULL
protein	NULL
,	NULL
an	NULL
E1	NULL
ubiquitin	NULL
activating	NULL
enzyme	NULL
,	NULL
heat	NULL
shock	NULL
protein	NULL
hsp70	NULL
,	NULL
an	NULL
HLA-B	NULL
associated	NULL
transcript	NULL
,	NULL
a	NULL
protease	NULL
,	NULL
an	NULL
ORF	NULL
within	NULL
an	NULL
intron	NULL
of	NULL
ABL	NULL
,	NULL
an	NULL
ion	NULL
channel	NULL
protein	NULL
,	NULL
a	NULL
senescent	NULL
fibroblast	NULL
cDNA	NULL
,	NULL
and	NULL
TRADD	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
others	NULL
were	NULL
novel	NULL
cDNAs	NULL
.	NULL

All	NULL
of	NULL
the	NULL
cDNA-encoded	NULL
proteins	NULL
interacted	NULL
with	NULL
full-length	NULL
LMP1	NULL
carboxyl	NULL
terminus	NULL
GALA-DBD-LMP1	NULL
(	NULL
182-386	NULL
)	NULL
.	NULL

When	NULL
tested	NULL
for	NULL
specificity	NULL
for	NULL
wild-type	NULL
TES2	NULL
,	NULL
one	NULL
of	NULL
the	NULL
cDNAs	NULL
failed	NULL
to	NULL
interact	NULL
with	NULL
isoleucine-mutated	NULL
LMP1	NULL
fusion	NULL
proteins	NULL
GALA-DBD-LMP1	NULL
(	NULL
355-383ID	NULL
)	NULL
or	NULL
GALA-DBD-LMP1	NULL
(	NULL
182-3831D	NULL
)	NULL
.	NULL

That	NULL
cDNA	NULL
encoded	NULL
the	NULL
TRADD	NULL
(	NULL
residues	NULL
195-312	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
its	NULL
unique	NULL
specificity	NULL
for	NULL
wild-type	NULL
TES2	NULL
,	NULL
TRADD	NULL
is	NULL
the	NULL
most	NULL
likely	NULL
cellular	NULL
mediator	NULL
of	NULL
TES2	NULL
effects	NULL
.	NULL

TRADD	NULL
Associates	NULL
Specifically	NULL
with	NULL
Wild-Type	NULL
TES2	NULL
in	NULL
293	NULL
Cells	NULL
and	NULL
LCLs	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
association	NULL
of	NULL
TRADD	NULL
with	NULL
wild-type	NULL
TES2	NULL
in	NULL
human	NULL
cells	NULL
,	NULL
antibody	NULL
to	NULL
Flag	NULL
was	NULL
used	NULL
to	NULL
immune	NULL
precipitate	NULL
F-LMP1	NULL
or	NULL
F-LMP1-ID	NULL
from	NULL
293	NULL
cells	NULL
cotransfected	NULL
with	NULL
myc-tagged	NULL
TRADD	NULL
vector	NULL
DNA	NULL
and	NULL
FLMP1	NULL
or	NULL
F-LMP1-ID	NULL
vector	NULL
DNAs	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

In	NULL
the	NULL
unfractionated	NULL
input	NULL
cell	NULL
lysates	NULL
,	NULL
myc-TRADD	NULL
was	NULL
expressed	NULL
at	NULL
similar	NULL
levels	NULL
in	NULL
the	NULL
respective	NULL
cotransfected	NULL
cells	NULL
.	NULL

F-LMP1	NULL
and	NULL
F	NULL
Medical	NULL
Sciences	NULL
:	NULL
Izumi	NULL
and	NULL
Kieff	NULL
A	NULL
&	NULL
__	NULL
ELMP1	NULL
é	NULL
FALMP1-ID	NULL
F-LMP1-FFD	NULL
§	NULL
11	NULL
12	NULL
21	NULL
%	NULL
go	NULL
1	NULL
20	NULL
3	NULL
4	NULL
14	NULL
12	NULL
14	NULL
14	NULL
15	NULL
16	NULL
kb	NULL
ah	NULL
#	NULL
#	NULL
-	NULL
-C	NULL
@	NULL
e	NULL
«	NULL
~-	NULL
m	NULL
@	NULL
OG	NULL
#	NULL
g	NULL
se	NULL
«	NULL
-a	NULL
€	NULL
ta	NULL
Gp	NULL
wh	NULL
wh	NULL
=	NULL
>	NULL
=	NULL
>	NULL
am	NULL
i	NULL
F-LMP1-ID	NULL
&	NULL
FLMP1	NULL
__	NULL
3	NULL
F-LMP1-FFD	NULL
E3	NULL
kDa	NULL
P3HR-1	NULL
_	NULL
1.1	NULL
1.2	NULL
21	NULL
1	NULL
2	NULL
3	NULL
4	NULL
1.1	NULL
1.2	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Characterization	NULL
of	NULL
LMP1	NULL
in	NULL
infected	NULL
LCLs	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Southern	NULL
blot	NULL
analysis	NULL
of	NULL
EBV	NULL
recombinant	NULL
infected	NULL
LCLs	NULL
.	NULL

DNA	NULL
cut	NULL
with	NULL
Seel	NULL
and	NULL
Mlul	NULL
was	NULL
Southern	NULL
blot-probed	NULL
with	NULL
EBV	NULL
MixI	NULL
DNA	NULL
(	NULL
nucleotide	NULL
167,129	NULL
to	NULL
169,560	NULL
)	NULL
,	NULL
which	NULL
comprises	NULL
LMP1	NULL
DNA	NULL
.	NULL

A	NULL
2.4-kb	NULL
DNA	NULL
from	NULL
P3HR-1	NULL
cells	NULL
and	NULL
a	NULL
wild-type	NULL
EBV-transformed	NULL
LCL	NULL
is	NULL
hybridized	NULL
by	NULL
the	NULL
probe	NULL
.	NULL

In	NULL
LCLs	NULL
F-LMP1	NULL
1.1	NULL
,	NULL
1.2	NULL
,	NULL
and	NULL
2.1	NULL
,	NULL
which	NULL
are	NULL
infected	NULL
with	NULL
an	NULL
F-LMP1	NULL
recombinant	NULL
from	NULL
F-LMP1-1	NULL
or	NULL
F-LMP1-2	NULL
LCL	NULL
,	NULL
a	NULL
SacI	NULL
site	NULL
near	NULL
the	NULL
Flag	NULL
codons	NULL
results	NULL
in	NULL
a	NULL
2.3-kb	NULL
DNA	NULL
whereas	NULL
the	NULL
0.16-kb	NULL
DNA	NULL
ran	NULL
off	NULL
.	NULL

In	NULL
coinfected	NULL
LCLs	NULL
F-LMP1-ID	NULL
1-4	NULL
or	NULL
in	NULL
singly	NULL
infected	NULL
LCLs	NULL
F-LMP1-FFD	NULL
1.1-1.6	NULL
,	NULL
which	NULL
are	NULL
infected	NULL
with	NULL
an	NULL
F-LMP1-FFD	NULL
recombinant	NULL
from	NULL
F-LMP1-FFD-1	NULL
LCL	NULL
,	NULL
F-LMP1-ID	NULL
,	NULL
and	NULL
F-LMP1-FFD	NULL
DNAs	NULL
,	NULL
have	NULL
a	NULL
second	NULL
SacI	NULL
site	NULL
near	NULL
the	NULL
last	NULL
codon	NULL
,	NULL
resulting	NULL
in	NULL
1.2-	NULL
and	NULL
1.1-kb	NULL
DNAs	NULL
whereas	NULL
the	NULL
0.16-kb	NULL
DNA	NULL
ran	NULL
off	NULL
.	NULL

The	NULL
2.4-kb	NULL
DNA	NULL
in	NULL
LCL	NULL
s	NULL
F-LMP1-ID	NULL
1-4	NULL
is	NULL
P3HR-1	NULL
LMP1	NULL
DNA	NULL
.	NULL

Markers	NULL
in	NULL
kb	NULL
are	NULL
at	NULL
left	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Immunoblot	NULL
analysis	NULL
of	NULL
LMP1	NULL
.	NULL

Proteins	NULL
from	NULL
5	NULL
x	NULL
10+	NULL
cells	NULL
were	NULL
size-separated	NULL
,	NULL
blotted	NULL
to	NULL
filters	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antibody	NULL
to	NULL
Flag	NULL
.	NULL

A	NULL
60-kDa	NULL
band	NULL
in	NULL
LCLs	NULL
F-LMP1	NULL
1.1	NULL
,	NULL
1.2	NULL
and	NULL
2.1	NULL
,	NULL
F-LMP1-ID	NULL
1-4	NULL
,	NULL
and	NULL
E-LMP1-FFD	NULL
1.1	NULL
and	NULL
1.2	NULL
is	NULL
Flag-LMP1	NULL
(	NULL
wild	NULL
type	NULL
or	NULL
mutant	NULL
)	NULL
.	NULL

A	NULL
standard	NULL
in	NULL
kDa	NULL
is	NULL
noted	NULL
at	NULL
left	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Immunofluorescent	NULL
staining	NULL
of	NULL
cells	NULL
with	NULL
antibody	NULL
to	NULL
Flag	NULL
.	NULL

(	NULL
C1	NULL
)	NULL
F-LMP1-ID-1	NULL
,	NULL
an	NULL
LCL	NULL
coinfected	NULL
with	NULL
P3HR-1	NULL
and	NULL
F-LMP1-ID	NULL
recombinant	NULL
.	NULL

(	NULL
C2	NULL
)	NULL
F-LMP1	NULL
1.1	NULL
,	NULL
an	NULL
LCL	NULL
infected	NULL
with	NULL
F-LMP1	NULL
recombinant	NULL
only	NULL
.	NULL

(	NULL
C3	NULL
)	NULL
P3HR-1	NULL
that	NULL
expresses	NULL
LMP1	NULL
.	NULL

(	NULL
C4	NULL
)	NULL
LCL	NULL
infected	NULL
with	NULL
wild-type	NULL
EBV	NULL
that	NULL
expresses	NULL
LMP1	NULL
without	NULL
Flag	NULL
.	NULL

LMP1-ID	NULL
also	NULL
were	NULL
expressed	NULL
at	NULL
similar	NULL
levels	NULL
in	NULL
the	NULL
respective	NULL
cotransfected	NULL
cells	NULL
and	NULL
were	NULL
immune-precipitated	NULL
with	NULL
similar	NULL
efficiency	NULL
.	NULL

TRADD	NULL
,	NULL
however	NULL
,	NULL
coprecipitated	NULL
with	NULL
F-LMP1	NULL
but	NULL
not	NULL
with	NULL
F-LMP1-ID	NULL
.	NULL

In	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
F-LMP1-FFD	NULL
and	NULL
an	NULL
F-LMP1	NULL
with	NULL
a	NULL
proline	NULL
to	NULL
alanine	NULL
mutation	NULL
within	NULL
a	NULL
site	NULL
near	NULL
TES2	NULL
that	NULL
resembles	NULL
a	NULL
TRAF	NULL
binding	NULL
motif	NULL
(	NULL
see	NULL
below	NULL
)	NULL
also	NULL
coimmune-precipitate	NULL
TRADD	NULL
.	NULL

Because	NULL
F-LMP1	NULL
and	NULL
F-LMP1-FFD	NULL
are	NULL
transforming	NULL
LMP1	NULL
genes	NULL
whereas	NULL
F-LMP1-ID	NULL
is	NULL
not	NULL
,	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
-	NULL
12595	NULL
A	NULL
Input	NULL
Unbound	NULL
Immune	NULL
Ppt	NULL
(	NULL
0.7	NULL
%	NULL
)	NULL
(	NULL
0.7	NULL
%	NULL
)	NULL
(	NULL
40	NULL
%	NULL
)	NULL
(	NULL
=	NULL
]	NULL
al	NULL
o	NULL
&	NULL
-	NULL
&	NULL
-	NULL
Lo	NULL
&	NULL
&	NULL
f	NULL
S	NULL
-	NULL
S	NULL
-	NULL
So	NULL
S	NULL
3	NULL
3	NULL
as	NULL
od	NULL
~d	NULL
wl	NULL
-4	NULL
-d	NULL
wo	NULL
0	NULL
w	NULL
u.	NULL
u.	NULL
u.	NULL
u.	NULL
TRADD	NULL
@	NULL
R	NULL
Wt	NULL
-	NULL
ams	NULL
.	NULL

ame	NULL
m	NULL
%	NULL
wer	NULL
ge	NULL
we	NULL
#	NULL
@	NULL
B	NULL
Input	NULL
Unbound	NULL
Immune	NULL
Ppt	NULL
i	NULL
§	NULL
-	NULL
i	NULL
sx	NULL
5100	NULL
§	NULL
1	NULL
§	NULL
-	NULL
i	NULL
S	NULL
LL	NULL
«	NULL
-J	NULL
LL	NULL
_J	NULL
LL	NULL
Mik	NULL
0.1.02	NULL
0.4	NULL
O8	NULL
0.1	NULL
0.4	NULL
5	NULL
15	NULL
%	NULL
LMP1	NULL
'	NULL
.	NULL

‘	NULL
-	NULL
;	NULL
-	NULL
l	NULL
.	NULL

M	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Specific	NULL
coprecipitation	NULL
of	NULL
TRADD	NULL
with	NULL
F-LMP1	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
pRKS-myc-TRADD	NULL
and	NULL
pSGS-based	NULL
F-LMP1	NULL
or	NULL
F-LMP1-ID	NULL
vector	NULL
DNAs	NULL
.	NULL

Nonidet	NULL
P-40-solubilized	NULL
proteins	NULL
were	NULL
incubated	NULL
with	NULL
M2	NULL
antibody	NULL
to	NULL
Flag	NULL
coupled	NULL
to	NULL
beads	NULL
(	NULL
Kodak	NULL
)	NULL
.	NULL

M2	NULL
beads	NULL
were	NULL
washed	NULL
,	NULL
and	NULL
precipitated	NULL
proteins	NULL
were	NULL
solubilized	NULL
and	NULL
immunoblot-analyzed	NULL
with	NULL
9E10	NULL
antibody	NULL
to	NULL
myc-TRADD	NULL
or	NULL
$	NULL
12	NULL
antibody	NULL
to	NULL
LMP1	NULL
.	NULL

Unfractionated	NULL
cell	NULL
proteins	NULL
are	NULL
inputs	NULL
,	NULL
and	NULL
proteins	NULL
not	NULL
precipitated	NULL
with	NULL
M2	NULL
beads	NULL
are	NULL
unbound	NULL
.	NULL

Percentages	NULL
indicate	NULL
fraction	NULL
of	NULL
total	NULL
sample	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Coprecipitation	NULL
of	NULL
TRADD	NULL
with	NULL
F-LMP1	NULL
.	NULL

LCL	NULL
s	NULL
(	NULL
1.5	NULL
x	NULL
108	NULL
cells	NULL
)	NULL
infected	NULL
with	NULL
an	NULL
F-LMP1	NULL
EBV	NULL
recombinant	NULL
or	NULL
with	NULL
a	NULL
wild-type	NULL
LMP1	NULL
EBV	NULL
recombinant	NULL
were	NULL
solubilized	NULL
in	NULL
buffer	NULL
containing	NULL
Brij	NULL
58	NULL
and	NULL
incubated	NULL
with	NULL
M2	NULL
beads	NULL
.	NULL

Precipitated	NULL
proteins	NULL
were	NULL
solubilized	NULL
and	NULL
Western	NULL
blot-analyzed	NULL
with	NULL
antisera	NULL
to	NULL
TRADD	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
or	NULL
$	NULL
12	NULL
antibody	NULL
to	NULL
LMP1	NULL
.	NULL

Unfractionated	NULL
cell	NULL
proteins	NULL
are	NULL
inputs	NULL
and	NULL
proteins	NULL
not	NULL
precipitated	NULL
with	NULL
M2	NULL
beads	NULL
are	NULL
unbound	NULL
.	NULL

Percentages	NULL
indicate	NULL
fraction	NULL
of	NULL
total	NULL
sample	NULL
.	NULL

these	NULL
results	NULL
further	NULL
indicate	NULL
TRADD	NULL
is	NULL
the	NULL
most	NULL
likely	NULL
cellular	NULL
mediator	NULL
of	NULL
TES2	NULL
effects	NULL
.	NULL

The	NULL
association	NULL
of	NULL
TRADD	NULL
with	NULL
F-LMP1	NULL
in	NULL
EBV	NULL
recombi-nant-transformed	NULL
LCLs	NULL
also	NULL
was	NULL
evaluated	NULL
by	NULL
immune-precipitating	NULL
F-LMP1	NULL
with	NULL
Flag	NULL
antibody	NULL
and	NULL
analyzing	NULL
precipitates	NULL
by	NULL
Western	NULL
blot	NULL
with	NULL
antibodies	NULL
to	NULL
LMP1	NULL
or	NULL
TRADD	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

An	NULL
LCL	NULL
infected	NULL
with	NULL
a	NULL
secondary	NULL
recombinant	NULL
that	NULL
has	NULL
a	NULL
complete	NULL
EBV	NULL
genome	NULL
and	NULL
LMP1	NULL
without	NULL
Flag	NULL
was	NULL
analyzed	NULL
as	NULL
control	NULL
.	NULL

In	NULL
the	NULL
unfractionated	NULL
input	NULL
cell	NULL
lysates	NULL
,	NULL
TRADD	NULL
was	NULL
present	NULL
at	NULL
similar	NULL
levels	NULL
in	NULL
the	NULL
two	NULL
LCLs	NULL
.	NULL

F-LMP1	NULL
and	NULL
LMP1	NULL
were	NULL
also	NULL
present	NULL
at	NULL
similar	NULL
levels	NULL
in	NULL
input	NULL
lysates	NULL
from	NULL
the	NULL
respective	NULL
LCLs	NULL
.	NULL

Flag	NULL
antibody	NULL
specifically	NULL
immune-precipitates	NULL
F-LMP1	NULL
and	NULL
coimmune	NULL
precipitates	NULL
TRADD	NULL
with	NULL
F-LMP1I	NULL
.	NULL

Taking	NULL
into	NULL
account	NULL
the	NULL
efficiency	NULL
of	NULL
F-LMP1	NULL
precipitation	NULL
(	NULL
25	NULL
%	NULL
)	NULL
,	NULL
4	NULL
%	NULL
of	NULL
TRADD	NULL
is	NULL
constitutively	NULL
associated	NULL
with	NULL
F-LMP1	NULL
in	NULL
LCLs	NULL
transformed	NULL
by	NULL
F-LMP1	NULL
recombinant	NULL
EBV	NULL
.	NULL

NF-xB	NULL
Is	NULL
Activated	NULL
by	NULL
TES2	NULL
and	NULL
TRADD	NULL
Mediates	NULL
NF-B	NULL
Activation	NULL
from	NULL
TES2	NULL
.	NULL

Because	NULL
TES2	NULL
maps	NULL
at	NULL
the	NULL
end	NULL
of	NULL
carboxyl	NULL
terminus	NULL
in	NULL
a	NULL
region	NULL
previously	NULL
implicated	NULL
in	NULL
high-level	NULL
NF-kB	NULL
activation	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
and	NULL
TRADD	NULL
mediates	NULL
NF-KB	NULL
activation	NULL
from	NULL
TNFR1	NULL
(	NULL
32	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
TRADD	NULL
and	NULL
TES2	NULL
in	NULL
mediating	NULL
NF-kB	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

In	NULL
293	NULL
cells	NULL
,	NULL
F-LMP1	NULL
induces	NULL
high-level	NULL
NF-KB	NULL
activation	NULL
whereas	NULL
a	NULL
Flag-LMP1-TES1	NULL
expression	NULL
vector	NULL
[	NULL
F-LMP1	NULL
(	NULL
1-231	NULL
)	NULL
,	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
]	NULL
induces	NULL
low-level	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
residues	NULL
that	NULL
include	NULL
the	NULL
repetitive	NULL
motif	NULL
to	NULL
TES1	NULL
in	NULL
vector	NULL
F-LMP1	NULL
(	NULL
1-351	NULL
)	NULL
contributes	NULL
little	NULL
to	NULL
TES1l-mediated	NULL
NF-KB	NULL
activation	NULL
whereas	NULL
F-LMP1	NULL
deleted	NULL
for	NULL
TES1	NULL
and	NULL
the	NULL
repetitive	NULL
motif	NULL
(	NULL
F-LMP1A	NULL
)	NULL
was	NULL
nearly	NULL
equal	NULL
to	NULL
F-LMP1	NULL
.	NULL

Further	NULL
,	NULL
F-LMP1-FFD	NULL
was	NULL
similar	NULL
to	NULL
F-LMP1	NULL
whereas	NULL
F-LMP1-ID	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
low	NULL
levels	NULL
mediated	NULL
by	NULL
TES1	NULL
.	NULL

Most	NULL
strikingly	NULL
,	NULL
high-level	NULL
NF-KB	NULL
activation	NULL
by	NULL
Flag-LMP1-TES2	NULL
expression	NULL
vector	NULL
F-LMP1A	NULL
was	NULL
completely	NULL
ablated	NULL
by	NULL
the	NULL
YYD	NULL
to	NULL
12596	NULL
-	NULL
Medical	NULL
Sciences	NULL
:	NULL
Izumi	NULL
and	NULL
Kieff	NULL
F-LMP1	NULL
(	NULL
1-231	NULL
)	NULL
F-LMP1A-ID	NULL
F-LMP1-ID	NULL
TRADD	NULL
(	NULL
ug	NULL
)	NULL
0	NULL
5	NULL
20	NULL
o	NULL
5	NULL
20	NULL
pSGS	NULL
_	NULL
@	NULL
@	NULL
rump	NULL
F-LMP1-D	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

(	NULL
4	NULL
)	NULL
F-LMP1	NULL
expression	NULL
in	NULL
293	NULL
cells	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Five	NULL
million	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pSGS	NULL
or	NULL
pSGS-LMP1	NULL
vector	NULL
DNA	NULL
,	NULL
2.5	NULL
ug	NULL
of	NULL
3	NULL
%	NULL
X-B-L	NULL
luciferase	NULL
reporter	NULL
DNA	NULL
,	NULL
and	NULL
2.5	NULL
ug	NULL
of	NULL
glucokinase	NULL
promoter/B-galactosidase	NULL
reporter	NULL
DNA	NULL
as	NULL
control	NULL
.	NULL

Residues	NULL
of	NULL
LMP1	NULL
are	NULL
indicated	NULL
within	NULL
parenthesis	NULL
,	NULL
A	NULL
indicates	NULL
deletion	NULL
of	NULL
residues	NULL
187-351	NULL
,	NULL
FFD	NULL
or	NULL
ID	NULL
indicates	NULL
replacement	NULL
of	NULL
Y3834	NULL
YDsge	NULL
,	NULL
and	NULL
P	NULL
>	NULL
A	NULL
indicates	NULL
P37	NULL
replaced	NULL
with	NULL
A	NULL
within	NULL
a	NULL
potential	NULL
TRAF	NULL
binding	NULL
site	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
analyzed	NULL
for	NULL
luciferase	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
-galactosidase	NULL
(	NULL
Tropix	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
on	NULL
an	NULL
Optocomp	NULL
I	NULL
luminometer	NULL
.	NULL

Immunoblots	NULL
probed	NULL
with	NULL
MS	NULL
antibody	NULL
to	NULL
Flag	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
indicated	NULL
that	NULL
LMP1	NULL
expressions	NULL
levels	NULL
were	NULL
similar	NULL
in	NULL
the	NULL
transfected	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
TRADD	NULL
and	NULL
F-LMP1	NULL
synergize	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
the	NULL
indicated	NULL
amounts	NULL
of	NULL
pSG5	NULL
or	NULL
pSGS5-F-LMP1	NULL
or	NULL
F-LMP-ID	NULL
vector	NULL
DNA	NULL
and	NULL
with	NULL
pRK5	NULL
or	NULL
pRKS-mycTRADD	NULL
vector	NULL
DNA	NULL
,	NULL
2.5	NULL
ug	NULL
of	NULL
3X	NULL
%	NULL
-	NULL
«	NULL
B-L	NULL
luciferase	NULL
reporter	NULL
DNA	NULL
,	NULL
and	NULL
2.5	NULL
ug	NULL
of	NULL
glucokinase	NULL
promoter/B-galactosidase	NULL
reporter	NULL
DNA	NULL
as	NULL
control	NULL
.	NULL

Lysates	NULL
were	NULL
analyzed	NULL
for	NULL
luciferase	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
-galactosidase	NULL
(	NULL
Tropix	NULL
)	NULL
on	NULL
an	NULL
Optocomp	NULL
I	NULL
luminometer	NULL
.	NULL

Immunoblots	NULL
probed	NULL
with	NULL
MS	NULL
antibody	NULL
to	NULL
Flag	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
indicated	NULL
that	NULL
LMP1	NULL
expressions	NULL
levels	NULL
were	NULL
similar	NULL
for	NULL
the	NULL
indicated	NULL
amounts	NULL
of	NULL
DNA	NULL
in	NULL
the	NULL
respective	NULL
transfected	NULL
293	NULL
cells	NULL
.	NULL

ID	NULL
mutation	NULL
(	NULL
F-LMP1A	NULL
vs.	NULL
F-LMP1A-ID	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
despite	NULL
resemblance	NULL
of	NULL
TES2	NULL
adjacent	NULL
residues	NULL
P	NULL
;	NULL
;	NULL
;	NULL
3XOQXS	NULL
;	NULL
53	NULL
to	NULL
the	NULL
core	NULL
element	NULL
of	NULL
a	NULL
TRAF	NULL
binding	NULL
site	NULL
(	NULL
18	NULL
,	NULL
31	NULL
)	NULL
,	NULL
mutation	NULL
of	NULL
P373	NULL
to	NULL
A	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
F-LMP1A-P	NULL
>	NULL
A	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
two	NULL
tyrosines	NULL
are	NULL
also	NULL
principal	NULL
elements	NULL
of	NULL
a	NULL
high-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
effector	NULL
site	NULL
,	NULL
and	NULL
taken	NULL
together	NULL
with	NULL
the	NULL
commune	NULL
precipitation	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
an	NULL
effector	NULL
role	NULL
for	NULL
TESZ	NULL
interaction	NULL
with	NULL
TRADD	NULL
in	NULL
mediating	NULL
transformation	NULL
and	NULL
activating	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

We	NULL
further	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
TRADD	NULL
as	NULL
a	NULL
mediator	NULL
of	NULL
TES2-	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

In	NULL
a	NULL
representative	NULL
293	NULL
cell	NULL
transfection	NULL
experiment	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
F-LMP1	NULL
or	NULL
TRADD	NULL
vector	NULL
DNAs	NULL
activated	NULL
NF-kB	NULL
30-fold	NULL
or	NULL
25-fold	NULL
,	NULL
respectively	NULL
.	NULL

Four	NULL
times	NULL
as	NULL
much	NULL
F-LMP1	NULL
DNA	NULL
activated	NULL
NF-kB	NULL
70-fold	NULL
whereas	NULL
four	NULL
times	NULL
as	NULL
much	NULL
TRADD	NULL
DNA	NULL
did	NULL
not	NULL
increase	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Cotransfecting	NULL
5	NULL
ug	NULL
of	NULL
F-LMP1	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
TRADD	NULL
vector	NULL
DNAs	NULL
activated	NULL
NF-KB	NULL
80-fold	NULL
,	NULL
which	NULL
is	NULL
greater	NULL
than	NULL
the	NULL
55-fold	NULL
sum	NULL
of	NULL
F-LMP1	NULL
plus	NULL
TRADD	NULL
activation	NULL
.	NULL

Even	NULL
more	NULL
striking	NULL
,	NULL
20	NULL
ug	NULL
of	NULL
F-LMP1	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
TRADD	NULL
DNA	NULL
activated	NULL
NF-	NULL
«	NULL
B	NULL
175-fold	NULL
,	NULL
which	NULL
is	NULL
substantially	NULL
greater	NULL
than	NULL
the	NULL
95-fold	NULL
expected	NULL
for	NULL
an	NULL
additive	NULL
effect	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
F-LMP1-ID	NULL
had	NULL
less	NULL
than	NULL
25	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
F-LMP1	NULL
,	NULL
and	NULL
F-LMP1-ID	NULL
did	NULL
not	NULL
synergize	NULL
with	NULL
TRADD	NULL
.	NULL

TRADD	NULL
interaction	NULL
with	NULL
F-LMP1	NULL
,	NULL
TRADD	NULL
synergy	NULL
with	NULL
F-LMP1	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
and	NULL
the	NULL
lack	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
of	NULL
interaction	NULL
or	NULL
synergy	NULL
with	NULL
F-LMP1-ID	NULL
are	NULL
biochemical	NULL
,	NULL
physiologic	NULL
,	NULL
and	NULL
genetic	NULL
evidence	NULL
that	NULL
TRADD	NULL
is	NULL
a	NULL
mediator	NULL
of	NULL
TES2Z-induced	NULL
NF-KB	NULL
activation	NULL
and	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

Because	NULL
TRAF2	NULL
is	NULL
a	NULL
downstream	NULL
effector	NULL
of	NULL
TRADD-mediated	NULL
NF-KB	NULL
activation	NULL
from	NULL
TNFR1	NULL
(	NULL
25	NULL
,	NULL
32	NULL
)	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
TRAF2	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
on	NULL
TRADD	NULL
and	NULL
TES2	NULL
was	NULL
investigated	NULL
.	NULL

In	NULL
DNT/293	NULL
cells	NULL
,	NULL
a	NULL
293	NULL
cell	NULL
line	NULL
derivative	NULL
that	NULL
expresses	NULL
eight	NULL
times	NULL
more	NULL
dominant	NULL
negative	NULL
TRAFZA6-86	NULL
than	NULL
TRAF2	NULL
,	NULL
TRADD	NULL
activated	NULL
NF-KB	NULL
10-fold	NULL
or	NULL
44	NULL
%	NULL
less	NULL
than	NULL
in	NULL
293	NULL
cells	NULL
where	NULL
TRADD	NULL
activated	NULL
NF-	NULL
«	NULL
B	NULL
18-fold	NULL
(	NULL
mean	NULL
of	NULL
three	NULL
experiments	NULL
)	NULL
.	NULL

This	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
previously	NULL
observed	NULL
40	NULL
%	NULL
inhibition	NULL
by	NULL
dominant	NULL
negative	NULL
TRAF2AG6-86	NULL
on	NULL
LMP1A187-332	NULL
mediated	NULL
NF-KB	NULL
activation	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Significantly	NULL
,	NULL
TES2	NULL
and	NULL
TRADD	NULL
synergistic	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
DNT/293	NULL
cells	NULL
(	NULL
mean	NULL
24-fold	NULL
)	NULL
was	NULL
also	NULL
48	NULL
%	NULL
less	NULL
than	NULL
in	NULL
293	NULL
cells	NULL
(	NULL
mean	NULL
46-fold	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
dominant	NULL
negative	NULL
TRAF2	NULL
has	NULL
similar	NULL
effects	NULL
on	NULL
TES2	NULL
,	NULL
TRADD	NULL
,	NULL
or	NULL
TES2	NULL
and	NULL
TRADD-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
taken	NULL
together	NULL
with	NULL
the	NULL
coimmune	NULL
precipitation	NULL
results	NULL
are	NULL
further	NULL
evidence	NULL
TESZ2	NULL
mediates	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
interaction	NULL
with	NULL
TRADD	NULL
and	NULL
TRADD	NULL
association	NULL
with	NULL
TRAFs	NULL
.	NULL

DISCUSSION	NULL
The	NULL
definition	NULL
of	NULL
a	NULL
second	NULL
LMP1	NULL
transformation	NULL
effector	NULL
site	NULL
(	NULL
TES2	NULL
)	NULL
involving	NULL
Y354	NULL
,	NULL
Y3585	NULL
and	NULL
the	NULL
finding	NULL
of	NULL
its	NULL
biochemical	NULL
and	NULL
physiologic	NULL
interaction	NULL
with	NULL
TRADD	NULL
adds	NULL
a	NULL
surprising	NULL
dimension	NULL
to	NULL
the	NULL
extent	NULL
to	NULL
which	NULL
LMP1	NULL
mimics	NULL
a	NULL
constitutively	NULL
activated	NULL
TNFR	NULL
to	NULL
mediate	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

This	NULL
model	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
is	NULL
based	NULL
on	NULL
the	NULL
findings	NULL
that	NULL
the	NULL
amino	NULL
terminus	NULL
tethers	NULL
the	NULL
first	NULL
transmembrane	NULL
domain	NULL
to	NULL
the	NULL
cytoplasm	NULL
,	NULL
the	NULL
six	NULL
transmembrane	NULL
domains	NULL
constitutively	NULL
aggregate	NULL
LMP1	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
and	NULL
aggregation	NULL
enables	NULL
TES1	NULL
to	NULL
constitutively	NULL
engage	NULL
TRAF3	NULL
,	NULL
1	NULL
,	NULL
and	NULL
2	NULL
to	NULL
mediate	NULL
initial	NULL
growth	NULL
transformation	NULL
of	NULL
B	NULL
lymphocytes	NULL
into	NULL
LCL	NULL
s	NULL
(	NULL
refs	NULL
.	NULL

10	NULL
,	NULL
12	NULL
,	NULL
and	NULL
15-18	NULL
;	NULL
K.	NULL
M.	NULL
Kaye	NULL
,	NULL
KL	NULL
.	NULL

,	NULL
E.	NULL
Johanssen	NULL
,	NULL
and	NULL
E.K	NULL
.	NULL

,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TNFR2	NULL
or	NULL
lymphotoxin	NULL
B	NULL
receptor	NULL
aggregation	NULL
,	NULL
TRAF	NULL
recruitment	NULL
,	NULL
and	NULL
subsequent	NULL
TRAF-mediated	NULL
effects	NULL
require	NULL
ligand	NULL
binding	NULL
(	NULL
20	NULL
,	NULL
25	NULL
)	NULL
.	NULL

We	NULL
now	NULL
find	NULL
that	NULL
TES2	NULL
mimics	NULL
TNFR1	NULL
by	NULL
appropriating	NULL
TRADD	NULL
as	NULL
its	NULL
signaling	NULL
adapter	NULL
.	NULL

Similar	NULL
to	NULL
TES1	NULL
association	NULL
with	NULL
TRAFs	NULL
,	NULL
LMP1	NULL
aggregation	NULL
enables	NULL
TES2	NULL
to	NULL
constitutively	NULL
engage	NULL
TRADD	NULL
to	NULL
enable	NULL
efficient	NULL
long-term	NULL
LCL	NULL
outgrowth	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
TNFR1	NULL
aggregation	NULL
,	NULL
TRADD	NULL
recruitment	NULL
,	NULL
and	NULL
TRADD-mediated	NULL
effects	NULL
require	NULL
TNF	NULL
(	NULL
19	NULL
,	NULL
32	NULL
,	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

An	NULL
important	NULL
aspect	NULL
of	NULL
the	NULL
interaction	NULL
of	NULL
TES2	NULL
with	NULL
TRADD	NULL
and	NULL
of	NULL
TES1	NULL
with	NULL
TR	NULL
AFs	NULL
is	NULL
how	NULL
these	NULL
two	NULL
sites	NULL
differentially	NULL
alter	NULL
cell	NULL
growth	NULL
.	NULL

TES1	NULL
mediates	NULL
low-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
as	NULL
measured	NULL
with	NULL
the	NULL
Igx	NULL
(	NULL
28	NULL
)	NULL
or	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complex	NULL
NF-kB	NULL
response	NULL
elements	NULL
(	NULL
18	NULL
,	NULL
27	NULL
)	NULL
,	NULL
which	NULL
preferentially	NULL
respond	NULL
to	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
/RelA	NULL
(	NULL
p65	NULL
)	NULL
dimers	NULL
.	NULL

Yet	NULL
,	NULL
TES1	NULL
mediates	NULL
initial	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
and	NULL
induces	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptors	NULL
in	NULL
C33	NULL
epithelial	NULL
cells	NULL
whereas	NULL
TESZ	NULL
mediates	NULL
high-level	NULL
NF-KB	NULL
activation	NULL
but	NULL
can	NULL
not	NULL
by	NULL
itself	NULL
mediate	NULL
B	NULL
lymphocyte	NULL
growth	NULL
transformation	NULL
or	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor	NULL
induction	NULL
(	NULL
17	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Clearly	NULL
,	NULL
TES1	NULL
and	NULL
TES2	NULL
are	NULL
transmitting	NULL
qualitatively	NULL
different	NULL
signals	NULL
that	NULL
are	NULL
not	NULL
fully	NULL
characterized	NULL
by	NULL
NF-KB	NULL
activation	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
Igx	NULL
or	NULL
class	NULL
1	NULL
major	NULL
histocompatibility	NULL
complex	NULL
NF-kB	NULL
response	NULL
elements	NULL
.	NULL

Whether	NULL
TRAF1	NULL
and	NULL
2	NULL
mediate	NULL
different	NULL
interactions	NULL
with	NULL
downstream	NULL
effectors	NULL
of	NULL
IxB	NULL
degradation	NULL
when	NULL
engaged	NULL
by	NULL
TES1	NULL
than	NULL
when	NULL
engaged	NULL
by	NULL
TES2	NULL
through	NULL
TRADD	NULL
or	NULL
whether	NULL
other	NULL
interactions	NULL
account	NULL
for	NULL
these	NULL
differences	NULL
remains	NULL
to	NULL
be	NULL
resolved	NULL
.	NULL

TRADD	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
only	NULL
in	NULL
part	NULL
mediated	NULL
by	NULL
a	NULL
direct	NULL
TRADD	NULL
interaction	NULL
with	NULL
TRAF1	NULL
and	NULL
2	NULL
.	NULL

TRADD	NULL
also	NULL
interacts	NULL
with	NULL
receptor	NULL
interacting	NULL
protein	NULL
,	NULL
which	NULL
can	NULL
recruit	NULL
TRAFs	NULL
and	NULL
substantially	NULL
augment	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
41	NULL
,	NULL
42	NULL
,	NULL
44	NULL
)	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
TRAFs	NULL
and	NULL
TRADD	NULL
as	NULL
the	NULL
proximal	NULL
effectors	NULL
of	NULL
TES1	NULL
and	NULL
TES2	NULL
are	NULL
important	NULL
steps	NULL
in	NULL
understanding	NULL
the	NULL
different	NULL
biochemical	NULL
and	NULL
genetic	NULL
effects	NULL
of	NULL
TES1	NULL
and	NULL
TES2	NULL
in	NULL
B	NULL
lympho-	NULL
Medical	NULL
Sciences	NULL
:	NULL
Izumi	NULL
and	NULL
Kieff	NULL
cyte	NULL
transformation	NULL
and	NULL
establish	NULL
a	NULL
basis	NULL
for	NULL
subsequent	NULL
analyses	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
the	NULL
difference	NULL
between	NULL
TES1	NULL
and	NULL
TES2	NULL
.	NULL

The	NULL
biochemical	NULL
and	NULL
genetic	NULL
data	NULL
reported	NULL
here	NULL
affirm	NULL
a	NULL
central	NULL
role	NULL
for	NULL
high-level	NULL
NF-kB	NULL
activation	NULL
from	NULL
TESZ	NULL
in	NULL
enabling	NULL
efficient	NULL
long-term	NULL
LCL	NULL
outgrowth	NULL
.	NULL

F-LMP1-ID	NULL
is	NULL
clearly	NULL
deficient	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
and	NULL
transformation	NULL
whereas	NULL
F-LMP1-FFD	NULL
is	NULL
similar	NULL
to	NULL
F-LMP1	NULL
for	NULL
TRADD	NULL
association	NULL
,	NULL
NF-kB	NULL
activation	NULL
,	NULL
and	NULL
transformation	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
found	NULL
that	NULL
those	NULL
cells	NULL
that	NULL
establish	NULL
long-term	NULL
outgrowth	NULL
after	NULL
infection	NULL
with	NULL
MS231	NULL
recombinant	NULL
that	NULL
has	NULL
only	NULL
TES1	NULL
have	NULL
high-level	NULL
NF-KB	NULL
activation	NULL
similar	NULL
to	NULL
wild-type	NULL
EBV	NULL
-transformed	NULL
LCLs	NULL
(	NULL
K.M	NULL
.	NULL

Kaye	NULL
,	NULL
KL	NULL
,	NULL
E.	NULL
Johanssen	NULL
,	NULL
and	NULL
EK	NULL
.	NULL

,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
high-level	NULL
NF-kB	NULL
activation	NULL
mediated	NULL
by	NULL
TES2	NULL
engagement	NULL
of	NULL
TRADD	NULL
or	NULL
by	NULL
underlying	NULL
viral	NULL
or	NULL
cellular	NULL
changes	NULL
appear	NULL
to	NULL
be	NULL
important	NULL
in	NULL
the	NULL
fully	NULL
transformed	NULL
LCL	NULL
phenotype	NULL
.	NULL

Such	NULL
a	NULL
role	NULL
for	NULL
NF-kB	NULL
in	NULL
EBV-mediated	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
role	NULL
of	NULL
NF-kB	NULL
in	NULL
normal	NULL
lymphocyte	NULL
growth	NULL
control	NULL
,	NULL
differ-entiation	NULL
,	NULL
and	NULL
development	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

NF-KB	NULL
can	NULL
alter	NULL
the	NULL
transcription	NULL
of	NULL
growth	NULL
regulatory	NULL
genes	NULL
such	NULL
as	NULL
c-myc	NULL
,	NULL
cytokines	NULL
such	NULL
as	NULL
interleukin	NULL
2	NULL
,	NULL
interleukin	NULL
6	NULL
,	NULL
granulocyte-colony	NULL
stimulating	NULL
factor	NULL
,	NULL
and	NULL
granulocyte/macrophage-colony	NULL
stimulating	NULL
factor	NULL
,	NULL
and	NULL
anti-apoptotic	NULL
factors	NULL
such	NULL
as	NULL
A20	NULL
(	NULL
45	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B-related	NULL
proteins	NULL
also	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
malignancy	NULL
.	NULL

Retroviral	NULL
v-re/	NULL
induces	NULL
lymphomas	NULL
in	NULL
chickens	NULL
whereas	NULL
activating	NULL
chromosomal	NULL
translocations	NULL
of	NULL
NFKB2	NULL
or	NULL
bel-3	NULL
are	NULL
associated	NULL
with	NULL
human	NULL
lymphomas	NULL
.	NULL

Moreover	NULL
,	NULL
human	NULL
T-lymphotrophic	NULL
virus-1	NULL
infection	NULL
,	NULL
fax-mediated	NULL
NF-KB	NULL
activation	NULL
,	NULL
and	NULL
dysregulated	NULL
lymphocyte	NULL
proliferation	NULL
are	NULL
significant	NULL
early	NULL
events	NULL
in	NULL
the	NULL
causation	NULL
of	NULL
adult	NULL
T	NULL
cell	NULL
leukemia	NULL
.	NULL

But	NULL
,	NULL
high-level	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
per	NULL
se	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
EBV-mediated	NULL
growth	NULL
transformation	NULL
because	NULL
LMP1	NULL
deleted	NULL
of	NULL
TES1	NULL
retains	NULL
high-level	NULL
NF-B	NULL
activation	NULL
but	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
B	NULL
lymphocyte	NULL
transformation	NULL
(	NULL
17	NULL
)	NULL
.	NULL

TRADD	NULL
is	NULL
a	NULL
mediator	NULL
of	NULL
TES2	NULL
effects	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
and	NULL
growth	NULL
transformation	NULL
and	NULL
transduces	NULL
death	NULL
signals	NULL
from	NULL
TNFR1	NULL
.	NULL

TNF	NULL
induces	NULL
TRADD	NULL
to	NULL
recruit	NULL
fas-associated	NULL
death	NULL
domain	NULL
protein	NULL
(	NULL
FADD	NULL
)	NULL
,	NULL
which	NULL
effects	NULL
apoptosis	NULL
through	NULL
its	NULL
interaction	NULL
and	NULL
activation	NULL
of	NULL
caspases	NULL
(	NULL
42	NULL
)	NULL
.	NULL

LMP1	NULL
can	NULL
have	NULL
toxic	NULL
effects	NULL
when	NULL
highly	NULL
expressed	NULL
(	NULL
46	NULL
)	NULL
,	NULL
and	NULL
this	NULL
could	NULL
be	NULL
caused	NULL
by	NULL
TRADD	NULL
interaction	NULL
.	NULL

However	NULL
,	NULL
TNFR1	NULL
and	NULL
LMP1	NULL
only	NULL
partially	NULL
overlap	NULL
in	NULL
inducing	NULL
apoptosis	NULL
.	NULL

In	NULL
most	NULL
cells	NULL
,	NULL
LMP1	NULL
expression	NULL
at	NULL
levels	NULL
similar	NULL
to	NULL
that	NULL
in	NULL
LCLs	NULL
activates	NULL
NF-KB	NULL
but	NULL
does	NULL
not	NULL
induce	NULL
apoptosis	NULL
.	NULL

Further	NULL
,	NULL
the	NULL
extent	NULL
to	NULL
which	NULL
LMP1	NULL
toxicity	NULL
is	NULL
attributable	NULL
to	NULL
apoptosis	NULL
is	NULL
uncertain	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
apoptosis	NULL
is	NULL
a	NULL
prominent	NULL
feature	NULL
of	NULL
TNF/TNFR1	NULL
activation	NULL
and	NULL
TRADD	NULL
overexpression	NULL
.	NULL

LMP1	NULL
and	NULL
TNFR	NULL
1	NULL
also	NULL
differ	NULL
in	NULL
the	NULL
biochemistry	NULL
of	NULL
their	NULL
interaction	NULL
with	NULL
TRADD	NULL
.	NULL

The	NULL
sequence	NULL
around	NULL
TES2	NULL
that	NULL
engages	NULL
TRADD	NULL
does	NULL
not	NULL
resemble	NULL
TNFR1	NULL
or	NULL
a	NULL
death	NULL
domain	NULL
.	NULL

Although	NULL
TNFR1	NULL
interaction	NULL
with	NULL
TRADD	NULL
can	NULL
propagate	NULL
a	NULL
death	NULL
domain	NULL
interaction	NULL
with	NULL
FADD	NULL
,	NULL
LMP1	NULL
interaction	NULL
with	NULL
TRADD	NULL
may	NULL
not	NULL
.	NULL

TESZ2	NULL
may	NULL
allosterically	NULL
alter	NULL
TRADD	NULL
and	NULL
resist	NULL
heteroaggregation	NULL
with	NULL
FADD	NULL
.	NULL

Alternatively	NULL
,	NULL
LMP1	NULL
may	NULL
actively	NULL
counter	NULL
cell	NULL
death	NULL
effectors	NULL
from	NULL
TRADD	NULL
through	NULL
the	NULL
anti-apoptotic	NULL
effects	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
A20	NULL
(	NULL
45	NULL
)	NULL
,	NULL
or	NULL
Bel-2	NULL
induction	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Erle	NULL
Robertson	NULL
,	NULL
Kenneth	NULL
Kaye	NULL
,	NULL
George	NULL
Mosialos	NULL
,	NULL
and	NULL
Ellen	NULL
Cahir	NULL
McFarland	NULL
contributed	NULL
to	NULL
this	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
Grant	NULL
CA47006-06	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
.	NULL

1	NULL
.	NULL

_	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
in	NULL
Fields	NULL
Virology	NULL
,	NULL
eds	NULL
.	NULL

Fields	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
Knipe	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Howley	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Chanock	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Melnick	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Monath	NULL
,	NULL
T.	NULL
P.	NULL
,	NULL
Roizman	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Straus	NULL
,	NULL
S.	NULL
(	NULL
Raven	NULL
,	NULL
Philadelphia	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

2343-2396	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
Licbowitz	NULL
,	NULL
D.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
43	NULL
,	NULL
831-840	NULL
.	NULL

Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
&	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Oncogene	NULL
2	NULL
,	NULL
461-467	NULL
.	NULL

Moorthy	NULL
,	NULL
R.	NULL
K.	NULL
&	NULL
Thorley-Lawson	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

67	NULL
,	NULL
1638-1646	NULL
.	NULL

5	NULL
.	NULL

Hammarskjold	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Simurda	NULL
,	NULL
M.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

66	NULL
,	NULL
6496-6501	NULL
.	NULL

6	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
Liebowitz	NULL
,	NULL
D.	NULL
,	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
Gregory	NULL
,	NULL
C.	NULL
,	NULL
Rickinson	NULL
,	NULL
A.	NULL
,	NULL
Larson	NULL
,	NULL
R.	NULL
,	NULL
Springer	NULL
,	NULL
T.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

62	NULL
,	NULL
4173-4184	NULL
.	NULL

>	NULL
pb	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
-	NULL
12597	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
Peng	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Huen	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Hardy	NULL
,	NULL
R.	NULL
,	NULL
Croom	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Lundgren	NULL
,	NULL
E.	NULL
&	NULL
Rickinson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

68	NULL
,	NULL
5602-5612	NULL
.	NULL

Wilson	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Weinberg	NULL
,	NULL
W.	NULL
,	NULL
Johnson	NULL
,	NULL
R.	NULL
,	NULL
Yuspa	NULL
,	NULL
S.	NULL
&	NULL
Levine	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
61	NULL
,	NULL
1315-1327	NULL
.	NULL

Dawson	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
Rickinson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Young	NULL
,	NULL
L.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
344	NULL
,	NULL
777-780	NULL
.	NULL

Kaye	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Izumi	NULL
,	NULL
K.	NULL
M.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Nail	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
9150-9154	NULL
.	NULL

Rickinson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
in	NULL
Fields	NULL
Virology	NULL
,	NULL
eds	NULL
.	NULL

Fields	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
Knipe	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Howley	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Chanock	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Melnick	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Monath	NULL
,	NULL
T.	NULL
P.	NULL
,	NULL
Roizman	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Straus	NULL
,	NULL
S.	NULL
(	NULL
Raven	NULL
,	NULL
Philadelphia	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

2397-2446	NULL
.	NULL

Izumi	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Kaye	NULL
,	NULL
K.	NULL
M.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

68	NULL
,	NULL
4369-4376	NULL
.	NULL

Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
&	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Oncogene	NULL
4	NULL
,	NULL
67-74	NULL
.	NULL

Liebowitz	NULL
,	NULL
D.	NULL
,	NULL
Mannick	NULL
,	NULL
J.	NULL
,	NULL
Takada	NULL
,	NULL
K.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

66	NULL
,	NULL
4612-4616	NULL
.	NULL

Kaye	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Izumi	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Mosialos	NULL
,	NULL
G.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
675-683	NULL
.	NULL

Mosialos	NULL
,	NULL
G.	NULL
,	NULL
Birkenbach	NULL
,	NULL
M.	NULL
,	NULL
Yalamanchili	NULL
,	NULL
R.	NULL
,	NULL
VanArsdale	NULL
,	NULL
T.	NULL
,	NULL
Ware	NULL
,	NULL
C.	NULL
&	NULL
Kicff	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
389-399	NULL
.	NULL

Izumi	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Kaye	NULL
,	NULL
K.	NULL
M.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
1447-1452	NULL
.	NULL

Devergne	NULL
,	NULL
O.	NULL
,	NULL
Hatzivassiliou	NULL
,	NULL
E.	NULL
,	NULL
Izumi	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Kaye	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Kleijnen	NULL
,	NULL
M.	NULL
F	NULL
Kicff	NULL
,	NULL
E.	NULL
&	NULL
Mosmlos	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Mal	NULL
Cell	NULL
Biol	NULL
.	NULL

16	NULL
,	NULL
7098-7108	NULL
.	NULL

Shu	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
Takeuchi	NULL
,	NULL
M.	NULL
&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Nail	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
,	NULL
13973-13978	NULL
.	NULL

VanArsdale	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
VanArsdale	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Force	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
Walter	NULL
,	NULL
B.	NULL
N.	NULL
,	NULL
Mosialos	NULL
,	NULL
G.	NULL
,	NULL
Kieff	NULL
,	NULL
E.	NULL
,	NULL
Reed	NULL
,	NULL
J.	NULL
C.	NULL
&	NULL
Ware	NULL
,	NULL
C.	NULL
F.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
2460-2465	NULL
.	NULL

Cheng	NULL
,	NULL
G.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

10	NULL
,	NULL
963-973	NULL
.	NULL

Banchereau	NULL
,	NULL
J.	NULL
,	NULL
Bazan	NULL
,	NULL
F.	NULL
,	NULL
Blanchard	NULL
,	NULL
D.	NULL
,	NULL
Briere	NULL
,	NULL
F.	NULL
,	NULL
Galizzi	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
van	NULL
Kooten	NULL
,	NULL
C.	NULL
,	NULL
Liu	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
Rousset	NULL
,	NULL
F.	NULL
&	NULL
Saeland	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
881-922	NULL
.	NULL

Kehry	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
2345-2348	NULL
.	NULL

Noelle	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Immunity	NULL
4	NULL
,	NULL
415-419	NULL
.	NULL

Rothe	NULL
,	NULL
M.	NULL
,	NULL
Sarma	NULL
,	NULL
V.	NULL
,	NULL
Dixit	NULL
,	NULL
V.	NULL
M.	NULL
&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1995	NULL
)	NULL
Science	NULL
269	NULL
,	NULL
1424-1427	NULL
.	NULL

Kaye	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Devergne	NULL
,	NULL
O.	NULL
,	NULL
Harada	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Izumi	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Yalamanchili	NULL
,	NULL
R.	NULL
,	NULL
Kieff	NULL
,	NULL
E.	NULL
&	NULL
Mosialos	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
,	NULL
11085-11090	NULL
.	NULL

Mitchell	NULL
,	NULL
T.	NULL
&	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
2968-2976	NULL
.	NULL

Huen	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Henderson	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Croom	NULL
,	NULL
C.	NULL
D.	NULL
&	NULL
Rowe	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Oncogene	NULL
10	NULL
,	NULL
549-560	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
in	NULL
Annual	NULL
Review	NULL
of	NULL
Immunology	NULL
(	NULL
Annual	NULL
Reviews	NULL
,	NULL
Inc.	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
Vol	NULL
.	NULL

12	NULL
,	NULL
pp	NULL
.	NULL

141-179	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
in	NULL
Annual	NULL
Review	NULL
of	NULL
Immunology	NULL
(	NULL
Annual	NULL
Reviews	NULL
,	NULL
Inc.	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
Vol	NULL
.	NULL

14	NULL
,	NULL
pp	NULL
.	NULL

649-683	NULL
.	NULL

Franken	NULL
,	NULL
M.	NULL
,	NULL
Devergne	NULL
,	NULL
O.	NULL
,	NULL
Rosenzweig	NULL
,	NULL
M.	NULL
,	NULL
Annis	NULL
,	NULL
B.	NULL
,	NULL
Kieff	NULL
,	NULL
E.	NULL
&	NULL
Wang	NULL
,	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

24	NULL
,	NULL
1879-1885	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
,	NULL
Xiong	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
495-504	NULL
.	NULL

Tomkinson	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

66	NULL
,	NULL
2893-2903	NULL
.	NULL

Tomkinson	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

66	NULL
,	NULL
780-789	NULL
.	NULL

Tomkinson	NULL
,	NULL
B.	NULL
,	NULL
Robertson	NULL
,	NULL
E.	NULL
,	NULL
Yalamanchili	NULL
,	NULL
R.	NULL
,	NULL
Longnecker	NULL
,	NULL
R.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

67	NULL
,	NULL
7298-7306	NULL
.	NULL

Durfee	NULL
,	NULL
T.	NULL
,	NULL
Becherer	NULL
,	NULL
K.	NULL
,	NULL
Chen	NULL
,	NULL
P.-L.	NULL
,	NULL
Yeh	NULL
,	NULL
S.	NULL
,	NULL
Yang	NULL
,	NULL
Y.	NULL
,	NULL
Kilburn	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Lee	NULL
,	NULL
W.	NULL
&	NULL
Elledge	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
555-569	NULL
.	NULL

Cohen	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
Wang	NULL
,	NULL
F.	NULL
,	NULL
Mannick	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
9558-9562	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
&	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
340	NULL
,	NULL
393-397	NULL
.	NULL

Robertson	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Tomkinson	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

68	NULL
,	NULL
1449-1458	NULL
.	NULL

Liebowitz	NULL
,	NULL
D.	NULL
,	NULL
Wang	NULL
,	NULL
D.	NULL
&	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

58	NULL
,	NULL
233-237	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
,	NULL
Huang	NULL
,	NULL
J.	NULL
,	NULL
Shu	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
Baichwal	NULL
,	NULL
V.	NULL
&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1996	NULL
)	NULL
Immunity	NULL
4	NULL
,	NULL
387-396	NULL
.	NULL

Hsu	NULL
,	NULL
H.	NULL
,	NULL
Shu	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
Pan	NULL
,	NULL
M.	NULL
G.	NULL
&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1996	NULL
)	NULL
Cell	NULL
84	NULL
,	NULL
299-308	NULL
.	NULL

Miller	NULL
,	NULL
W.	NULL
,	NULL
Mosialos	NULL
,	NULL
G.	NULL
,	NULL
Kieff	NULL
,	NULL
E.	NULL
&	NULL
Raab-Traub	NULL
,	NULL
N.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
586-594	NULL
.	NULL

Ting	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Pimentel	NULL
,	NULL
M.	NULL
F.	NULL
&	NULL
Seed	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
6189-6196	NULL
.	NULL

Laherty	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Hu	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Opipari	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Wang	NULL
,	NULL
F.	NULL
&	NULL
Dixit	NULL
,	NULL
V.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
24157-24160	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
,	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

63	NULL
,	NULL
2469-2475	NULL
.	NULL

